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2. Summary 
The immune system plays a significant role during tumorigenesis with evidence for a 
promoting as well as a suppressing role. Indeed, the amount and location of tumor-infiltrating Th1 
and cytotoxic T cells is a strong positive prognostic factor in multiple types of human cancers. 
However, advanced tumors have intrinsic capacities to evade immune attack (immunoediting) as 
well as extrinsic mechanisms including a suppressive microenvironment, which also dampens 
tumor-specific immunity.  
The main aim of immunotherapy is to improve protective effector function of tumor-specific 
T cells, which relies on 3 signals: Stimulation of the TCR receptor (signal 1), costimulation (signal 
2) and supportive cytokines (signal 3). In the context of cancer, naïve T cells are insufficiently 
primed and become progressively dysfunctional or tolerant most probably due to the low quality of 
these 3 signals. Although the requirements for T cell activation are well characterized, how to 
prevent tolerance in the context of cancer remains unclear. 
Boosting antitumor responses by blocking PD-1 or CTLA-4 results in durable clinical 
responses only in a limited proportion of cancer patients suggesting that other pathways must be 
targeted to improve clinical efficacy. We therefore aimed to develop an approach to prime tumor-
specific CD8+ T cells, prevent induction of tolerance and achieve control of large, established 
tumors. We used mice that develop autochthonous prostate cancer (TRAMP mice) as well as mice 
carrying advanced melanoma (B16) and combined different immune interventions with adoptive 
transfer of tumor-specific TCR transgenic CD8+ T cells.  
We found that the combination of agonistic anti-CD40 + IL-2/anti-IL-2 complexes + IL-
12Fc was a distinctively effective treatment with respect to priming protective, tumor-specific 
immunity and eradicating tumors at advanced disease stage when given together with adoptively 
transferred tumor-specific T cells. We propose that improving signals 2 (costimulation) and 3 
(cytokines) together with fresh tumor-specific rather than dysfunctional pre-existing memory T 
cells represents a potent therapy for advanced cancer.  
The second part of this thesis describes the generation of a novel inducible mouse model of 
cancer. 
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3. Zusammenfassung 
Das Immunsystem spielt eine bedeutende Rolle bei der Tumorgenese und es gibt Belege 
dafür, dass das Immunsystem sowohl eine fördernde, als auch eine unterdrückende Rolle bei der 
Tumorentstehung spielt. In der Tat sind Anzahl und Lokalisation der tumor-infiltrierenden Th1 und 
zytotoxischen T-Zellen ein bedeutender positiver prognostischer Faktor bei verschiedenen 
Krebserkrankungen des Menschen. Fortgeschrittene Tumore haben intrinsische Kapazitäten 
("immunoediting") und extrinsische Mechanismen um sich gegen Angriffe des Immunsystems zu 
wehren; unter anderem führt die suppressive Tumormikroumgebung dazu, dass die tumor-
spezifische Immunität gehemmt wird. 
Das Ziel der Immuntherapie ist es die Effektorfunktion von tumor-spezifischen T-Zellen zu 
verbessern, welche auf 3 Signale setzt: Stimulation des T-Zell-Rezeptors (Signal 1), Kostimulation 
(Signal 2) und Freisetzung von unterstützenden Zytokinen (Signal 3). Im Zusammenhang mit Krebs 
werden naive T-Zellen unzureichend "geprimed" und aufgrund der geringen Qualität der 3 Signale 
zunehmend dysfunktional oder tolerogen. Obwohl die Voraussetzungen der T-Zellaktivierung gut 
charakterisiert sind, ist es weiterhin unklar wie die Toleranzentstehung im Zusammenhang mit 
Krebs verhindert werden kann. 
Eine Verbesserung der Antitumorimmunität durch Blockierung von PD-1 oder CTLA-4 
ergibt nur in einem begrenzten Anteil an Krebspatienten einen dauerhaften klinischen Erfolg, was 
darauf hindeutet, dass andere Wege gewählt werden müssen um die klinische Wirksamkeit gezielt 
zu verbessern. Daher bestand das Ziel darin, einen Therapieansatz zu entwickeln, der die tumor-
spezifischen CD8+ T-Zellen primed, Toleranzentstehung verhindert und das Wachstum von großen, 
etablierten Tumoren kontrolliert. Hierfür verwendeten wir ein Mausmodell für autochthonen 
Prostatakrebs (TRAMP Mäuse), sowie Mäuse mit fortgeschrittenem Melanom (B16) und 
kombinierten verschiedene Immuninterventionen mit einem adoptiven Transfer von tumor-
spezifischen T-Zell-Rezeptor transgenen CD8+ T-Zellen.  
Wir fanden heraus, dass die Kombination von agonistischem anti-CD40 + IL-2 / anti-IL-2-
Komplexe + IL-12Fc einen bedeutenden Behandlungeffekt erzielte. Die Kombination führte zu 
einer schützenden, tumor-spezifischen Immunität und zu einer Ausrottung von Tumoren im 
fortgeschrittenem Krankheitsstadium, wenn sie zusammen mit adoptiv transferierten tumor-
spezifischen T-Zellen gegeben wurde. Wir schlagen vor, dass die Verbesserung der Signale 2 
(Kostimulation) und 3 (Zytokine) zusammen mit tumor-spezifischen, und nicht mit dysfunktionalen 
vorbestehenden Gedächtnis-T-Zellen, eine wirksame Therapie bei Krebs im fortgeschrittenen 
Stadium darstellt. Der zweite Teil der Arbeit beschreibt die Erzeugung eines neuartigen 
induzierbaren Tumor-Mausmodell. 
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5. Introduction 
5.1. A brief history of cancer 
Since the oldest description of cancer in an Egyptian papyrus dating back to the seventeenth 
century B.C., our understanding of this disease has tremendously improved. Although the papyrus 
is the first documentation of the disease, the first usage of the word cancer goes back to the father of 
medicine, a Greek physician from the fourth century B.C. named Hippocrates. Almost four 
millenniums later, the treatment of cancer remains, in many cases, regrettably similar to what is 
written in the Edwin Smith Papyrus, which denotes it as an incurable ailment (1). 
Nowadays, cancer figures in the leading causes of morbidity and mortality worldwide. For 
2012, it was estimated that 14 million new cancer cases were diagnosed globally and this figure is 
projected to grow by 70% in the next 2 decades (2). Advances in modern medicine significantly 
improved the expected survival of cancer patients, but many cancers remain incurable although a 
large proportion could be prevented. Indeed, a third of cancer-related deaths could be avoided by 
behavioral and dietary changes, with the main cancer risk factors consisting of a high body mass 
index, an unhealthy diet, a lack of physical activity and consumption of tobacco and alcohol.  
Even if cancer has been known for millenniums, our current understanding of it consists 
largely in the research discoveries made since Richard M. Nixon declared war on cancer with the 
National Cancer Act of 1971. Since this historical date, colossal investments over the globe 
accelerated the pace of research in the quest for developing better treatments. 
 
 
Figure 1. Some major milestones of the fight against cancer. 
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5.2. Our current view of cancer 
5.2.1. Hallmarks of cancer 
The transformation of a normal cell into a cancer cell consists of a multistep process starting 
with genetic aberrations that lead to gain- or loss-of-function mutations of crucial regulating genes 
(3, 4). The number and location of these mutations vary greatly among cancer types, but their 
common feature is that they allow the cell to progressively evolve towards a neoplastic state. The 
process is analogous to Darwinian selection and leads to the acquisition of several hallmark 
capabilities increasing the cell’s capacity to sustain proliferation, resist cell death, induce 
angiogenesis and activate invasion and metastasis mechanisms. These hallmarks were recently 
updated to acknowledge the important role of tumor-promoting inflammation, enhanced genomic 
instability, deregulated metabolism and avoidance of immune destruction in tumorigenesis. 
Collectively, these acquired features summarized in Figure 2 (4) dictate cancerous growth. This 
simple schematic of complex mechanisms provides a recent overview in which all pathways are 
under intense investigation to generate novel targeted therapies.  
 
 
Figure 2. Hallmarks of cancer (4). 
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5.2.2. Cancer immunosurveillance 
The growing comprehension of each of these processes has reshaped the way modern 
medicine tackles cancer and has triggered the expansion of promising areas of research. Although 
not new, the field of tumor immunology is one of them. In 1909, Paul Ehrlich suggested for the first 
time that the immune system was suppressing cancer development (5). Five decades later, Burnet 
and Thomas reformulated this theory as the “cancer immunosurveillance” hypothesis speculating 
that lymphocytes are sentinels of the host that continuously eliminate arising transformed cells (6-
8). This concept suffered early on from the lack of strong experimental evidence and was buried 
after the report that immunodeficient nude mice (9) don’t show increased frequency of spontaneous 
or chemically induced tumorigenesis (10). Multiple other studies (11-13) were conducted on this 
topic confirming Stutman’s results which provided highly convincing data leading to the 
abandonment of the immunosurveillance theory in the 1970’s. However, it is now clear that the 
limited knowledge available at that time about the immunologic impairments of nude mice 
misguided the scientific community on the immune defense to cancer.  
 
5.2.3. Cancer immunoediting 
Recently, tumor evasion of immune surveillance arose again as a major topic in cancer 
research and comes from convincing new data in mice and humans that proved the importance of 
the immune system in controlling cancer. The questions are not anymore about the existence of the 
process, but rather how to translate it to improve cancer therapies. To progress in this direction, it is 
crucial to decipher the complex interplay between tumors and the immune system. On the one hand, 
recent results indicated that both the innate and adaptive arms of the immune system contribute to 
tumor cell control (14-17). On the other hand, tumor immunity has been shown to have tumor-
promoting roles through the selection of tumor variants that escaped immune recognition and 
elimination (15, 16, 18). This double-edge sword consisting of tumor destruction and promotion of 
tumor growth has been summarized into the cancer immunoediting process (Figure 3).  
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Figure 3. The three Es of cancer immunoediting (16). 
 
As illustrated in Figure 3, the phases of elimination, equilibrium and escape are thought to 
occur in a sequential manner following a Darwinian model of immunological pressure on tumor 
cells. However, the concept doesn’t exclude that some cells may directly enter either into 
equilibrium or escape phase.  
 
5.2.3.1. Elimination 
The elimination represents the phase in which innate and adaptive immunity cooperate to 
sense and destroy arising transformed cells. It is not fully understood how the immune system 
detects such cells, but multiple propositions have been made. Multiple danger signals were 
described including type I interferons (19), damage-associated molecular pattern molecules 
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(DAMPs) released from dying cells and damaged tissues (20) as well as NKG2D stress ligands 
(21). All these mechanisms eventually converge towards the release of pro-inflammatory and 
immunomodulatory cytokines that supports the establishment of a tumor-specific adaptive immune 
response. Although it has been reported in some models that innate immunity was sufficient to 
protect against cancer growth (21-23), in most experimental systems, an effective cancer 
immunosurveillance requires the additional involvement of adaptive immunity. The strongest 
evidence for the elimination phase in humans consists of the spontaneous regression of melanoma 
lesions accompanied by the clonal expansion of tumor-specific T cells (24, 25). However, cases of 
spontaneous tumor regression remain rare events. 
 
5.2.3.2. Equilibrium 
The equilibrium phase consists of a balance between tumor control by the immune system 
and tumor growth yielding a net result neither in favor of elimination nor progression. 
Immunoediting takes place during this latency phase with the immune system eliminating tumor 
cells that are more immunogenic and therefore selects for variants with a higher potential to evade 
immune control. This process was demonstrated in mice with two different approaches. The first 
experimental proof came from transplantation of tumors that grew in wild-type or immunodeficient 
mice with a targeted disruption of the recombination-activating gene-2 (RAG2) and therefore lacks 
functional B, T and NKT cells. When these tumors were transplanted into wild-type recipients, the 
tumor growth differed depending on their origin. As illustrated in Figure 4, tumors growing in 
RAG2-/- mice were considered unedited, rendering them more susceptible to rejection in an 
immunocompetent host while edited primary tumors that grew in wild-type mice could evade 
immune control in immunocompetent recipients (18).  
A second strong evidence of the equilibrium phase was demonstrated using low dose of the 
chemical carcinogen 3’-methylcholanthrene (MCA) to induce carcinogenesis in mice. As shown in 
Figure 5, the equilibrium represented by the absence of detectable tumors in MCA-treated animals 
can be disrupted by antibodies depleting T cells and neutralizing IFN- showing the importance of 
constant control by adaptive immunity over long periods of time. This is observed in humans for 
example by the development of donor-derived cancers in organ transplant recipients (26). Further 
clinical observations supporting the existence of the equilibrium phase in humans are represented 
by the long period between successful treatment, detection of minimal residual disease and relapse 
(27, 28). 
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Figure 4. Immunoediting of cancer cells (16). 
 
Figure 5. Antibody-induced equilibrium disruption in mice (29). 
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5.2.3.3. Escape 
The escape of tumor cells from immune control occurs when the equilibrium can’t be 
maintained and tumor-specific immunity becomes insufficient to limit cancer progression. Multiple 
intrinsic and extrinsic mechanisms have been identified that promote tumor’s escape from immune 
attack. Inherent capacities acquired by tumor cells, for example reduced immune recognition 
through the loss of tumor antigens (30), impaired antigen presentation, improved resistance to cell 
death and expressions of surface molecules or soluble factors creating an immunosuppressive 
microenvironment can all contribute to tumor cell survival (31). Additionally, extrinsic mechanisms 
favoring tumor survival and growth include numerous cell types recruited to tumors (MDSCs, Treg, 
macrophages) and the factors they produce locally that impact on tumor-specific immunity. The 
number of molecules contributing to the escape phase continuously increases and these pathways 
represents attractive targets for cancer therapy (31). 
 
Figure 6. Mechanisms contributing to the escape of tumor cells (31). 
 
Although each step of cancer immunoediting is supported by strong evidence, it remains 
unclear how frequent and how rapidly these phases occur in humans. Recent data acquired using 
multiregion whole-genome sequencing of operable non-small cell lung cancers suggested a 
prolonged tumor latency period of at least 20 years before clinical detection in former smokers (32). 
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Certainly, the length of the equilibrium phase characterized by tumor dormancy and editing may 
vary significantly between patients and also among cancer types, but this strongly supports the 
rationale to continuously improve diagnostic methods to allow earlier detection. There is also 
clinical information supporting the existence of proliferative dormancy at premetastatic sites (27, 
33, 34).  
Therefore, the equilibrium phase which comprises an ongoing immune response would be, 
in theory, the best window to treat patients. Unfortunately, most patients are diagnosed in the escape 
phase, when the equilibrium is compromised and the tumor progresses in a microenvironment rich 
in immunosuppressive signals that may dampen the efficacy of current therapies. Ongoing efforts in 
the field aim at restoring this equilibrium phase through immunomodulation and in the best case 
scenario, to eradicate cancer.  
 
5.3. Harnessing the immune system against cancer 
5.3.1. Immune infiltrate: prognostic significance 
In several human cancers, it has been demonstrated 
that the type, density and localization of immune cells 
infiltrating the primary tumor constitute strong prognostic 
factors of overall survival relevant at any stages of the 
clinical disease (35, 36). 
 More specifically, high infiltration by memory T 
cells of the Th1 and cytotoxic types provides patients with 
better survival chances as shown in Figure 7 (37). 
Concerning other immune cell subsets, no consensus has 
been established, but the majority of publications consider 
Th2, Th17 and Treg cells to be detrimental to the patients. 
With the complexity of the tumor micro-environment, it 
remains unclear if T lymphocytes priming is limited to 
secondary lymphoid organs before homing at the tumor 
site, but it was recently suggested that tertiary lymphoid 
structures (TLS) may support priming of adaptive 
immunity (38-40). The abundance of these structures composed of mature dendritic cells adjacent to 
T cell clusters and B cell proliferating germinal center correlates with better survival in multiple 
cancer types and with increased CD8 T cell infiltration, which indirectly supports this hypothesis 
(40-43). In accordance with this theory, it was recently reported that the density of TLS-associated 
Figure 7. Association of immune 
infiltrate with prognosis in 
various types of cancer (37). 
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mature DC correlates with a gene signature related to T cell activation of Th1 and cytotoxic 
phenotype in human primary lung tumors (39). It will be interesting to know if the TLS adjacent to 
tumors represent an essential part of the immune contexture to mount or support an effective tumor-
specific immune response.  
Recent studies provided evidence that responses to checkpoint blockade immunotherapy are 
better when pre-existing tumor-specific immunity is present in cancer patients (44-47). 
Interestingly, these results showed that adaptive immune responses observed in mice and patients 
treated with checkpoint blockade targeted tumor-specific mutant antigens. In line with these 
findings, the mutational load in cancer patients was shown to be associated with the degree of 
clinical benefit to such therapy (47). The discovery of a neoantigen landscape that is specifically 
present in strong responders to anti-CTLA-4 therapy provides a rationale for examining exomes of 
patients for whom immunotherapy is being considered. These tumor-specific mutant antigens also 
offer an opportunity to develop personalized cancer-specific vaccines. 
 
5.3.2. The 3 signals crucial for T cell priming 
Multiple events are required for optimal priming of T cells. First, the T cell must interact 
with its cognate peptide on the antigen-presenting cell (APC) through TCR-mediated binding of the 
MHC complex presenting the peptide epitope. This event occurs through the establishment of a 
supra molecular activation cluster (SMAC) also known as the immunological synapse between the 
T cell and the antigen-presenting cell (48-50).  
During this cell-cell contact, the second event consists of crucial costimulatory signals to 
dictate differentiation and proliferation of the T cell. At this step, the maturation status of the APC 
is a major factor regulating the balance between costimulatory and coinhibitory signaling (51). 
Figure 8 illustrates the numerous molecules influencing this balance. These early signaling events 
through the TCR and costimulatory molecules trigger a cascade of intracellular events in T cells 
including tyrosine kinase activation, inositol phospholipid hydrolysis and a surge in intracellular 
Ca2+ (52). Downstream, the CBM complex composed of Card11, Malt1 and Bcl10 amplifies the 
signal through its particular scaffold structure. This complex is a central player in T cell activation 
and leads to optimal NF-κB activation (52). At the same time, multiple other pathways culminate in 
the translocation to the nucleus of several transcription factors involved in the production of IL-2 
and other T cell activation signature genes programming a transcription profile that regulates 
cytoskeletal rearrangements, cellular metabolism, cell cycle and cell differentiation (52-54). 
Autocrine and paracrine IL-2 represents one of the most important cytokine supporting T 
cell survival, proliferation and differentiation (55). Nonetheless, multiple other cytokines influence 
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T cell faith and constitute signal 3, which is mainly provided by IL-12 or type I interferons (56-58). 
Altogether, antigen affinity, costimulation and cytokine inputs dictate T cells expansion, 
differentiation into effector cells and establishment a memory population (59). 
 
Figure 8. Costimulatory and coinhibitory molecules on T cells and their target (60). 
 
5.3.3. Enhancing tumor-specific immunity through therapy 
As mentioned previously, both the innate and adaptive arms of the immune system can play 
a beneficial role in tumor control. Therefore, an optimal therapy should impact on both 
compartments to yield protective and long-lasting tumor-specific immunity.  
It is now clear that conventional therapies like radio- and chemotherapy previously thought 
to exert their efficacy mainly through direct toxicity to tumor cells also support tumor-specific 
immunity, which contributes to clinical responses (61-67). This suggests that immune stimulation 
can synergize with such therapies and multiple studies support this concept in mice (68-70), as well 
as in humans (71-78). Currently, this knowledge is being translated into a growing number of 
clinical trials, although trial results remain scarce so far.  
Immunotherapeutic approaches including vaccines (79), adoptive T cell transfers (80), 
induction of APC maturation (81, 82), checkpoint blockade (83, 84) and cytokines (85, 86) improve 
tumor-specific immunity in mice and humans to a certain extent, but objective clinical responses 
remain limited. Although promising, these results suggest that additional pathways need to be 
targeted to increase clinical efficacy. All of these approaches ultimately aim by different ways to 
improve the effector function of T cells which relies on the 3 signals previously mentioned: 
Stimulation of the TCR receptor (signal 1), costimulation (signal 2) and supportive cytokines 
(signal 3) (52). In the context of cancer, antigen-presenting cells do not adequately deliver signals 2 
and 3, which leads to robust, antigen-specific T cell tolerance (51, 56, 57, 87, 88). While the 
requirements for T cell activation are well characterized, the optimal way to prevent T cell tolerance 
in the context of cancer remains unclear.  
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5.4. Aims 
One of the current challenges in the field of cancer research resides in the difficulty to 
extrapolate preclinical findings to humans. This issue may never be solved completely, but during 
the past decade, the field gained awareness and understanding about the critical need for better 
preclinical cancer models (89-92). Spontaneous, autochthonous cancer models develop more slowly 
than subcutaneously injected cancers and give rise to cancer in the physiological tissue context, 
both of which mimic human cancer. 
This thesis focused on understanding and counteracting tumor-specific CD8+ T cell 
unresponsiveness in the context of cancer and two projects were pursued in parallel. The first part 
was dedicated to developing an immunotherapeutic intervention that results in priming of tumor-
specific CD8+ T cells, prevention of immune deviation and clinical response. This project was 
performed using a well-characterized autochthonous model of prostate cancer (TRAMP) (93). The 
carcinogenesis in this model is SV40 large T antigen (SV40LT)-dependent, which enabled the use 
of multiple SV40LT-related tools that were generated or acquired at the beginning of this study. In 
addition, prostate cancer represents the second leading cause of cancer deaths in men and remains 
the cancer with the highest incidence according to statistics collected by the American Cancer 
Society for 2014 (94). 
In line with the need for better models for cancer in different tissues, the second project of 
this thesis consisted of generating a new preclinical cancer model (ARTURO) to allow inducible 
tissue-specific tumorigenesis (CreERT/LoxP system) through the expression of SV40LT. 
 
5.5. Transgenic adenocarcinoma of the mouse prostate 
The TRAMP mouse (transgenic adenocarcinoma of the mouse prostate) develops 
autochthonous prostate cancer as a result of prostate-specific expression of SV40LT under the 
control of the rat probasin promoter (93). In this model, the expression of the large T antigen is 
induced upon sexual maturation of male mice since the promoter is androgen responsive. As 
illustrated in Figure 9, hemizygous transgenic animals progress through various phases of disease 
from mild intraepithelial hyperplasia at puberty to large malignant neoplasia within the appropriate 
microenvironment (95, 96). Histological grading in this model has been established and consists of 
6 stages described in Table 1 (95). The TRAMP model has attracted widespread attention in the last 
two decades due to its ability to closely mirror the multistep pathogenesis seen in man (97-99). 
Moreover, androgen-driven and developmentally regulated tumors transiently regress following 
androgen withdrawal, but subsequently relapse, paralleling the eventual occurrence of deadly 
hormone-independent prostate cancer observed in man (100, 101). Therefore, the TRAMP model 
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represents a clinically relevant murine model of prostate cancer. However, the TRAMP model has 
disadvantages including the lack of methods to quantify tumor load in live animals and the long 
timeframe of tumor development. These are obviously major drawbacks, as clinical response is the 
most relevant parameter for any therapy that aims to improve tumor-specific immunity. The use of 
ARTURO mice intended to solve this problem, because ARTURO mice allow non-invasive and 
repeated quantification of tumor load of Cre-recombined tumor cells expressing luciferase (luc) 
with the SV40LT. Early phases of my work also aimed at establishing novel experimental setups in 
TRAMP mice that would allow faster assessment of clinical efficacy. 
 
Figure 9. Progressive carcinogenesis in TRAMP mice (95, 96). 
 
Table 1. Histopathologic grading of TRAMP tumors, adapted from (95). 
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6. Results 
6.1. Effective immunotherapy of advanced cancer in mice 
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One Sentence Summary: Treatment with anti-CD40 + IL-2 complexes + IL-12 promotes priming 
of tumor-specific CD8+ T cells with sustained effector function, prevents induction of tolerance and 
has curative potential in mouse models of advanced cancer.  
 
Abstract: Naïve T cells are insufficiently primed and become progressively dysfunctional in the 
context of cancer. Boosting antitumor responses by blocking PD-1 or CTLA-4 results in durable 
clinical responses only in a limited proportion of cancer patients suggesting that other pathways 
must be targeted to improve clinical efficacy. Our preclinical study identified anti-CD40 + IL-2 
complexes + IL-12Fc as a uniquely efficacious treatment that prevents tolerance induction, 
promotes priming of sustained, protective tumor-specific CD8+ T cells and cures late-stage cancer 
when given together with adoptively transferred tumor-specific T cells. We propose that improving 
signals 2 (costimulation) and 3 (cytokines) together with fresh tumor-specific rather than 
dysfunctional pre-existing memory T cells represents a potent therapy for advanced cancer. 
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6.1.1. Introduction 
The immune system plays a significant role during tumorigenesis with evidence for a 
promoting as well as a suppressing role (1). Indeed, the amount and location of tumor-infiltrating 
Th1 and cytotoxic T cells is a strong positive prognostic factor in multiple types of human cancers 
(2). However, advanced tumors have intrinsic capacities to evade immune attack (immunoediting) 
as well as extrinsic mechanisms including a suppressive microenvironment, which also limits 
efficacy of conventional therapies (1). 
The fact that radio- and chemotherapy can support tumor-specific immunity suggests that 
immune stimulation synergizes with such therapies (3-5). Multiple immunotherapeutic approaches 
such as vaccines (6), adoptive cell transfers (7), induction of antigen-presenting cell (APC) 
maturation (8, 9), checkpoint blockade (10, 11) and cytokines (12, 13) showed some success in 
boosting tumor-specific immunity both in mice and humans, although objective clinical responses 
were scarce. The main aim of immunotherapy is improving protective effector function of tumor-
specific T cells, which relies on 3 signals: Stimulation of the TCR receptor (signal 1), costimulation 
(signal 2) and supportive cytokines (signal 3) (14). Immature dendritic cells (DCs) do not 
sufficiently provide signals 2 and 3 and induce robust, antigen-specific T cell tolerance (15-17). 
Although the requirements for T cell activation are well characterized, how to prevent tolerance in 
the context of cancer remains unclear.  
We therefore aimed to identify a way to prime tumor-specific CD8+ T cells, prevent 
induction of tolerance and achieve control of large, established tumors. We used TRAMP mice that 
develop autochthonous prostate cancer (18) combined with adoptive transfer of tumor-specific TCR 
transgenic CD8+ T cells (TCR-I) (19) as well as advanced B16 melanoma. We found that the 
combination of agonistic anti-CD40 + IL-2/anti-IL-2 complexes (IL-2cx) + IL-12Fc was a 
distinctively effective treatment with respect to priming protective, tumor-specific immunity and 
eradicating tumors at advanced disease stage. 
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6.1.2. Results  
Tumor-specific CD8+ T cells are insufficiently primed in tumor-bearing mice 
To study whether tumor-specific CD8+ T cells are primed to develop full effector function in 
the context of a large, established tumor, we adoptively transferred CFSE-labeled tumor-specific 
CD8+ T cells (TCR-I) into 13-14 weeks old male TRAMP (TG) mice and WT mice. TCR-I cells 
migrated into the prostate of TRAMP mice (Figures 1A and 1B) and proliferated in all organs 
analyzed as measured by CFSE dilution showing that TCR-I cells recognized their cognate antigen 
(Figure 1C). However, only a small proportion of TCR-I cells developed effector function as 
characterized by low IFN- production and degranulation (CD107a+) (Figures 1D and 1E). 
Furthermore, IFN- production decreased over time, whereas the co-inhibitory molecule PD-1 
increased (Figures 1D and 1F). Similar results were observed when TCR-I cells were transferred 
into TRAMP mice with an age ranging from 12 to 25 weeks (data not shown). Thus, in the context 
of cancer, CD8+ T cells are inefficiently primed and progressively lose their already limited effector 
function. 
Since proper T cell activation depends on antigen presentation by mature dendritic cells 
(DC) (17, 20), we tested whether insufficient DC maturation was responsible for poor CD8+ T cell 
priming using co-injection of agonistic anti-CD40 antibodies. Eight days after adoptive transfer, 
spleen, prostate draining lymph nodes (PDLNs) and prostate were harvested and analyzed by flow 
cytometry (Figure 2A). Compared to controls, co-injection of anti-CD40 resulted in a 45- to 90-fold 
increase in TCR-I numbers in all organs analyzed, whereas the number of tumor-infiltrating 
endogenous CD8+ T cells rose by 3-fold (Figure 2B). The frequency of IFN- producing cells was 
higher in the PDLNs and to some extent in the tumor (Figure 2C), as was the frequency of 
degranulating cells in the periphery (Figure 2D). Additionally, the amount of IFN- produced by 
TCR-I cells (IFN- GMFI of IFN-+ cells) increased significantly in every organ analyzed (Figure 
2C). Prostatic CD8+ to regulatory T cell (CD45.2+ CD4+ FoxP3+) ratio increased (Figure 2E) and 
PD-1 surface expression on TCR-I cells was reduced upon anti-CD40 treatment (Figure 2F). Anti-
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CD40 treatment had an opposite effect on the PD-1 surface expression of endogenous CD8+ T cells, 
which may indicate T cell activation. These data indicate that insufficient DC maturation precludes 
the development of effector function of tumor-specific CD8+ T cells in TRAMP mice. 
 
Naïve and effector tumor-specific CD8+ T cells lose function in tumor-bearing mice 
To investigate whether tolerance induction in the context of cancer is antigen-dependent, we 
co-transferred TCR-I and P14 cells (as control) into WT and TRAMP mice. All mice were 
subsequently infected with two recombinant vaccinia viruses, one coding for SV40LT206-215 (rVV-
I), the other for LCMV gp (rVV-G2), to trigger systemic responses in both transferred populations 
(Figure 3A). As expected, a high proportion of TCR-I and P14 cells in the spleen and PDLNs of 
WT mice produced IFN-. In contrast, responses of TCR-I, but not P14 cells, were significantly 
lower in TRAMP mice (Figures 3B and S1A-S1L), suggesting the induction of tumor-specific 
tolerance. PD-1 surface expression was elevated only on TCR-I cells of TRAMP mice, while P14 
cells had similar levels of PD-1 in WT and TRAMP mice (Figure 3C). Thus, antigen encounter by 
CD8+ T cells in the context of established cancer induces robust T cell tolerance, which cannot be 
overcome by subsequent viral challenge. 
Because adoptive T cell therapy is a rapidly evolving and promising approach to treat 
multiple human cancer types (7), we adoptively transferred tumor-specific CD8+ effector T cells, 
challenged mice 7 days later with rVV-I and assessed TCR-I function on day 12 (Figure 4A). Both 
in spleen and PDLNs of TRAMP mice, effector TCR-I cells displayed a 2-fold reduction of the 
frequency of IFN-+ cells compared to WT mice and produced significantly less IFN- on a per-cell 
basis (Figure 4B). However, prior activation of TCR-I cells prevented PD-1 upregulation in vivo 
(Figure 4C) as compared to naïve cells (Figure 3C). These findings indicate that both naïve and 
effector tumor-specific CD8+ T cells rapidly become functionally compromised in tumor-bearing 
mice although naïve T cells are more susceptible. 
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Preventing tolerance induction by immune intervention 
 The use of rVV-I infection is a robust read-out for tolerance. We used this set-up to identify 
interventions that prevent tolerance induction (Figure 5A). We tested combinations of different 
treatments such as complexes of recombinant murine IL-2 and S4B6 mAb (IL-2cx), recombinant 
murine IL-12 fused to murine IgG3 Fc (IL-12Fc), agonistic anti-CD40, blocking anti-CTLA-4 and 
anti-PD-1 mAbs. Data from 3 independent experiments were pooled and for purpose of comparison, 
we normalized the results to responses without intervention in WT (set to 100%) and TRAMP (set 
to 0%) (Figures S2A-S2C) for each of the 6 different read-outs used. Depending on the read-out, the 
individual treatments had different rankings (Tables S1, S2 and S3), suggesting that some 
interventions support proliferation and/or survival of TCR-I cells whereas others impact more on 
function, thus providing a rationale for combined use. Agonistic anti-CD40 was present in the 5 
best treatments and was also the most potent single agent therapy, underscoring the importance of 
APC activation. The combination composed of IL-2cx + IL-12Fc + anti-CD40 was the most potent 
regimen tested overall (Figure S2C and Table S3) with respect to TCR-I numbers (Figure 5B), IFN-
 production (Figure 5C), degranulation (Figure 5D) and concomitant reduction in PD-1 surface 
expression (Figure 5E). Thus, simultaneous targeting of multiple pathways prevents the induction of 
tumor-specific CD8+ T cell tolerance in tumor-bearing mice. 
 
Treatment with anti-CD40 + IL-2cx + IL-12Fc turns tolerance of local and systemic tumor-specific 
immunity into priming 
To investigate whether anti-CD40 + IL-2cx + IL-12Fc not only prevents tolerance induction 
but also promotes priming of tumor-specific CD8+ T cells in tumor-bearing mice, we transferred 
naïve TCR-I cells into TRAMP mice and started therapy on the same day (Figure 6A). One week 
after adoptive transfer, we found a significant increase in absolute numbers of TCR-I cells and in 
the frequency and quality of IFN- producing TCR-I cells in the periphery as well as at the tumor 
site of treated mice (Figures 6B and S3A), while high surface PD-1 expression was prevented upon 
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treatment (Figure S3B). None of the other combinations tested was as efficient as anti-CD40 + IL-
2cx + IL-12Fc (Figures S4A-S4F). 
To investigate whether this therapy can rescue tolerized TCR-I cells, we started treatment 2 
weeks after adoptive transfer and performed analysis a week later (Figure 6C). The combination of 
anti-CD40 + IL-2cx + IL-12Fc rescued tolerized TCR-I cells with respect to their numbers (Figure 
S3C), the frequency of IFN- producing TCR-I in the PDLNs and the per-cell production of IFN- 
in PDLNs and prostate (Figure 6D). A proportion of TCR-I cells in the prostate expressed lower 
levels of PD-1 in treated animals (Figure S3D). 
To investigate whether this combination sustains long-term tumor-specific immunity, we 
treated adoptively transferred mice for a week and analyzed 2 weeks later (Figure 6E). Again, the 
treated group showed superior responses in terms of absolute numbers (Figure S3E), frequency and 
intensity of IFN- production (Figure 6F) and PD-1 expression (Figure S3F) by TCR-I cells. On day 
21 after the start of the therapy, the treated mice had significantly reduced tumor burden compared 
to controls (Figures 6G and 6H). This reduction was not observed one week after treatment 
(prevention approach shown in Figure 6A) or when treatment was started 2 weeks after adoptive 
transfer (rescue approach shown in Figure 6C). Surprisingly, when combining the data from these 3 
different experimental set-ups (Figures 6A, 6C and 6E), we found an inverse correlation between 
the logarithms of IFN- GMFI and PD-1 GMFI restricted to IFN-+ TCR-I cells, with the strongest 
association (R2 = 0.9315) in the prostate (Figure S5). Thus, treatment with anti-CD40 + IL-2cx + 
IL-12Fc leads to clinical responses with durable local and systemic immunity. Also, tolerized 
tumor-specific CD8+ T cells were rescued to a limited extent, albeit without impact on tumor 
burden at the time point investigated. 
To investigate the impact of the treatment on endogenous tumor-specific CD8+ T cells, we 
used 3 well-characterized H-2b-restricted CD8 epitopes derived from SV40LT (21). Mice were 
treated as described (Figures 6A and 6C) and single cell suspensions from spleen, PDLNs and 
prostate were stimulated in vitro with the 3 pooled SV40LT peptides, followed by intracellular 
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staining for IFN-. Seven days after transfer, the frequency of IFN-+ endogenous CD8+ cells was 
significantly higher in treated mice compared to controls (Figure 7A) as were absolute counts of 
endogenous CD8+ T cells in the prostate (Figure 7B). However, this effect was short-lasting as it 
was not detected 2 weeks after cessation of therapy. Higher numbers of IFN- producing 
endogenous CD8+ T cells correlated with higher surface PD-1 levels as compared to the control 
group (Figures 7C and S6), in contrast to the observations with TCR-I cells (Figures 6C and S4). 
The highest endogenous CD8+ to Treg ratio was observed on day 21 (Figure 7D), but this was 
mainly due to the low number of Tregs in the prostate (Figure 7E). Because we only analyzed the 
response against three SV40LT-derived epitopes and ignored other potential tumor-specific 
antigens, we most likely underestimated the endogenous CD8+ T cell response to the tumor. Thus, 
anti-CD40 + IL-2cx + IL-12Fc also enhance endogenous tumor-specific immunity.  
 
Treatment with anti-CD40 + IL-2cx + IL-12Fc shows clinical efficacy in late-stage cancer models 
 We investigated the clinical efficacy of the therapy for advanced tumors using TRAMP mice 
and subcutaneously injected B16F10 syngeneic melanoma that does or doesn’t express ovalbumin 
(OVA) (Figures 8A and 8E).  
TRAMP mice were treated at the age of 20 weeks when all mice have prostatic 
intraepithelial neoplasia and 80% of mice show adenocarcinomas (22). While the control group had 
a median tumor-free survival of 32.3 weeks and median overall survival of 37.6 weeks, mice that 
received either TCR-I cells alone or TCR-I cells + anti-CD40 + IL-2cx + IL-12Fc had significantly 
prolonged survival (Figures 8B and 8C). Mice that received only TCR-I cells had a median tumor-
free survival of 41.3 weeks (vs control, p < 0.0001) and a median overall survival of 49.1 weeks (vs 
control, p = 0.0002). Strikingly, 85% (11/13) of the mice receiving TCR-I cells + anti-CD40 + IL-
2cx + IL-12Fc remained tumor-free and 100% were alive at 45 weeks of age (tumor-free and 
overall survival, p < 0.0001 vs control). Most importantly, tumor-free and overall survival of mice 
treated with TCR-I cells + anti-CD40 + IL-2cx + IL-12Fc were significantly improved compared to 
21 
 
adoptive transfer alone (p = 0.0055 and p = 0.0374, respectively). The combination therapy required 
concomitant adoptive transfer of TCR-I cells to have clinical efficacy in this late-stage therapeutic 
setting of autochthonous prostate cancer. A one-week treatment with anti-CD40 + IL-2cx + IL-12Fc 
with concomitant adoptive transfer of TCR-I cells induced long-lasting protective immunity, as 
transferred TCR-I cells were detectable in blood of treated mice more than 6 months after adoptive 
transfer, but not in mice receiving only TCR-I cells. Although comparison was not possible at this 
late timepoint, peripheral TCR-I cells remained functional in treated animals in terms of IFN- 
secretion and degranulation when restimulated with SV40LT206-215 peptide (Figure 8D). These data 
indicate that the combination therapy synergized strongly with adoptive transfer of TCR-I cells to 
eradicate advanced stage cancer in TRAMP mice and provided protective, long-lasting tumor-
specific immunity. 
The treatment of C57BL/6 mice bearing B16F10 or B16F10-OVA tumors started on day 13 
after tumor injection (tumor size ~40-50 mm2), a time at which single reagents cannot control tumor 
growth (23 and unpublished data). The median survival of B16F10-bearing mice treated with anti-
CD40 + IL-2cx + IL-12Fc nearly doubled (34 days) compared to the controls (18 days) (Figures 8F 
and S7A). In the case of B16F10-OVA tumors, some of the mice received adoptively transferred 
OT-I cells i.v. on day 13. Without anti-CD40 + IL-2cx + IL-12Fc, mice with B16F10-OVA tumors 
had a median survival time of 21 days whether they received OT-I cells or not. Treatment with anti-
CD40 + IL-2cx + IL-12Fc + OT-I cells prolonged the median survival to 52 days and cured 43% 
(3/7) of the mice (Figures 8G and S7B). Tumor rejection was accompanied by vitiligo indicating a 
strong and sustained response against melanocytes that did not extend beyond the initial site of 
tumor injection (Figure 8H). In this model, anti-CD40 and IL-2cx were given i.p. and IL-12Fc 
intratumoral. When all components were given i.p. using a 100-fold higher dose of IL-12Fc, we 
observed no cure although the median survival significantly increased (35 days vs 24 days) (data 
not shown). Thus, supporting tumor-specific CD8+ T cells on 3 levels (anti-CD40, IL-2 and IL-12) 
generates protective immunity that can eradicate advanced tumors. 
22 
 
6.1.3. Discussion  
The immune system plays an essential role in controlling cancer cells (1). The clinical 
response to drugs that modulate the immune system such as blockade of CTLA-4 and PD-1 or its 
ligands further illustrates that the immune system can be employed in the therapy of cancer (11, 24, 
25). However, only a fraction of the patients responds to such therapies, suggesting that additional 
pathways must be targeted to improve clinical efficacy.  
We identified the combination of anti-CD40 + IL-2cx + IL-12Fc as uniquely efficacious in 
inducing protective, long-lasting tumor-specific immunity of adoptively transferred and endogenous 
tumor-specific CD8+ T cells. This immune intervention had clinical efficacy in late stage preclinical 
cancer models and curative potential when combined with adoptive T cell transfer. 
Our observation that without intervention, naïve TCR-I cells proliferate upon adoptive 
transfer into TRAMP mice but are subsequently tolerized suggests that signals 2 (costimulation) 
and 3 (cytokines) rather than signal 1 (TCR) are limiting. Previous work has highlighted the critical 
importance of the CD40-CD40L axis in preventing T cell tolerance (20, 26). Our study confirms 
this since the 5 best therapies identified here comprised agonistic anti-CD40, which improves signal 
2 through induction of DC maturation.  
A major result of concomitant TCR and CD28 signaling is the production of IL-2 by T cells. 
However, IL-2 production is transient and Tregs compete with activated T cells for IL-2 (27), which 
may result in death of the latter due to IL-2 deprivation (28). This may be relevant especially in the 
tumor microenvironment, which usually contains high numbers of Tregs. Specific support to 
effector T cells is possible through the use of IL-2cx, which target IL-2 to antigen-experienced 
CD122high (IL-2R) T cells (29). 
While anti-CD40 + IL-2cx may support priming and expansion of tumor-specific CD8+ T 
cells in the context of advanced cancer, their differentiation into protective effectors requires 
additional signals such as IL-12 (signal 3) (16, 30). Accordingly, combining anti-CD40 and IL-2cx 
with IL-12Fc significantly improved the quality of tumor-specific T cells with respect to many 
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parameters. Altogether, our data are in line with recent work showing that T cell division destiny 
depends on the integrated quality of signals 1, 2 and 3 (31).  
Although APC maturation resulting in appropriate costimulation and local production of 
cytokines is essential and usually sufficient to prevent the induction of peripheral T cell tolerance, 
the immunosuppressive tumor microenvironment poses an additional challenge. For example, local 
overexpression of PD-1 ligands may negatively impact on T cell function. PD-1 was originally 
described as an activation marker on T cells (32), but later data showed that PD-1 acts as a 
coinhibitory molecule (33) involved in peripheral T cell tolerance (34) that is often used as a marker 
for exhausted T cells (35). TCR-I cells progressively upregulate the expression of PD-1 upon 
adoptive transfer into TRAMP mice, unless they are treated with immunostimulatory drugs. PD-1 
expression on TCR-I cells correlates negatively with IFN- production, in agreement with PD-1 
being a marker for T cell exhaustion/dysfuntion. However, endogenous CD8+ T cells showed a 
different behavior with respect to PD-1 expression: Treatment with anti-CD40 + IL-2cx + IL-12Fc 
resulted in increased IFN- production and PD-1 expression. Because the levels of PD-1 on 
endogenous CD8+ T cells in TRAMP mice treated with anti-CD40 + IL-2cx + IL-12Fc is 
substantially lower than that on TCR-I cells in untreated TRAMP mice, we propose that 
intermediate levels of PD-1 mark T cell activation, whereas very high levels indicate 
exhaustion/dysfunction supporting the view of PD-1 as a rheostat of immune responses (36). The 
apparently greater tendency of TCR-I cells to express very high levels of PD-1 in the context of 
advanced cancer when compared to endogenous CD8+ T cells may be related to TCR affinity (37). 
All interventions tested here had an impact on PD-1 expression, although to various extent, pointing 
to PD-1 as a central player in the negative feedback mechanism following activation. However, 
because not all interventions improved T cell responses, blocking PD-1 is not sufficient to sustain 
protective immunity. 
One of the biggest challenges in the field remains to reach maximal efficacy with 
manageable toxicity. Despite the fact that the combination of anti-CD40, IL-2cx and IL-12Fc was 
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well tolerated in mice, these reagents have severe side-effects at high doses in humans (38, 39). 
Such toxicities have limited the development of many candidate drugs in the past, but recently, less 
toxic molecules have been engineered and made their way into clinical trials. For example, the 
fusion of IL-12 to a tumor-specific antibody targeting it to necrotic regions of tumors showed 
promising efficacy in mice and better toxicity profile in cynomolgus monkeys than recombinant IL-
12 (40). Other examples include site-specific mutations of IL-2 altering its affinity towards IL-2R 
and losing the requirement for CD25 involvement in order to increase its activity on cytotoxic T 
cells and reduce it on regulatory T cells (41) or the use of IL-2cx as we did here, which have a 
better efficacy with reduced toxicity than recombinant IL-2 (29, 42). 
Recent studies suggested de novo priming towards tumor-specific mutant antigens in the 
context of checkpoint blockade as important predictors of response to immunotherapy (43-45). Our 
study supports the importance of de novo priming and showed that rescuing pre-existing tumor-
infiltrating CD8+ T cells is inefficient. Along this line, the relatively long lag phase before 
immunotherapy is effective may be explained by dependence on de novo priming: pre-existing 
immunity is presumably compromised and cannot be sufficiently boosted. Instead, efficacy may 
rely on new thymic emigrants (or adoptively transferred T cells) that encounter tumor-specific 
antigens in an immunogenic context, which can be achieved by targeting multiple pathways 
involved throughout T cell priming and differentiation. Indeed, our data show that treatment with 
anti-CD40 + IL-2cx + IL-12Fc during the first week of adoptive transfer results in clinical efficacy 
and maintenance of protective effector TCR-I cells over a period of at least 6 months in TRAMP 
mice with advanced cancer. One can speculate that the favorable effects of lympho- and 
myeloablation prior to adoptive transfer of tumor-specific T cells may enhance de novo priming 
because immunosuppressive and compromised cells are deleted (46). 
In conclusion, we have identified a novel therapeutic intervention for late-stage tumors that 
supports systemic and local tumor-specific immunity in a durable fashion and shows clinical 
responses. The efficacy of anti-CD40 + IL-2cx + IL-12Fc significantly outperformed all other 
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treatments we tested here and we think that combined improvement of signal 2 and 3 explains this 
result. To our knowledge, the combined therapy described here is the first example of successful 
curative treatment of late stage (day 13) B16F10 melanoma. Furthermore, our study shows survival 
benefit in the autochthonous and clinically relevant TRAMP model treated at an advanced disease 
stage (20 weeks) with only a single cycle of treatment with protective immunity lasting over 6 
months following transfer.  
We propose that an optimal cancer immunotherapy based on T cells should tackle 4 major 
obstacles. 1) The frequency of fresh tumor-specific T cells needs to be increased and adoptive 
transfer or cancer vaccines may represent optimal ways of achieving this goal. 2) Appropriate 
costimulation is essential. 3) Survival and differentiation of tumor-infiltrating T cells must be 
supported by local cytokine therapy. 4) Innovative delivery systems and careful dosage will be key 
enabling factors to limit treatment-related toxicities and achieve maximal efficacy. 
 
Materials and Methods 
Please refer to Supplementary Materials and Methods. 
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6.1.5. Figures and legends  
Fig. 1 
 
Figure 1. Tumor-specific TCR-I CD8+ T cells proliferate and migrate to the tumor but do not 
develop effector function. One million CD8+ TCR-I cells were adoptively transferred into 13-20 
weeks old male TRAMP or WT mice. (A) The percentage of TCR-I cells of CD8+ T cells in spleen, 
prostate-draining lymph nodes (PDLNs) and prostate 7 days after transfer. (B) Absolute number of 
CD8+ CD45.1+ TCR-I cells of live singlets per mg prostate 7 days after transfer. (C) Proliferation of 
TCR-I cells as measured by CFSE dilution in spleen, PDLNs and prostate 5 days after transfer. Two 
representative mice out of five are shown. (D) IFN- production in spleen, PDLNs and prostate by 
TCR-I cells at different time points after transfer. (E) Degranulation of TCR-I cells in spleen and 
PDLNs 8 days after transfer. (F) PD-1 surface expression on TCR-I cells in the prostate 5 and 12 
days after transfer. Two representative mice of 9 are shown. WT, open symbols (○); TRAMP, 
closed symbols (●). Symbols represent individual mice (n=4-5 per group) and data from one out of 
two independent experiments are shown. Horizontal lines represent mean values. 
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Fig. 2 
 
Figure 2. Agonistic anti-CD40 supports effector function of adoptively transferred tumor-
specific TCR-I cells. (A) One million TCR-I cells were adoptively transferred into 11-14 weeks old 
male TRAMP mice and anti-CD40 was administered as depicted. (B) Absolute number, (C) IFN- 
production and (D) degranulation of TCR-I and endogenous CD8+ cells in spleen, PDLNs and 
prostate 8 days after transfer. (E) Ratio of absolute number of CD8+ to Treg and (F) PD-1 surface 
expression of two representative mice is illustrated. Endogenous CD8+, open symbols (○); TCR-I, 
closed symbols (●). Symbols represent individual mice and data from one out of three experiments 
are shown. Horizontal lines represent mean values.  
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Fig. 3 
 
Figure 3. Tumor-specific naïve CD8+ T cells are tolerized in TRAMP mice. (A) One million 
TCR-I (CD45.1+2-) + one million P14 (CD45.1+2+) TCR transgenic CD8+ cells were adoptively 
transferred into 14-15 weeks old male TRAMP or WT mice. Mice were infected 7 days after 
adoptive transfer with a mixture of 106 PFU rVV-I + 106 PFU rVV-G2. TCR-I and P14 T cells were 
analyzed 5 days after infection. (B) IFN- production and (C) representative examples for PD-1 
surface expression of TCR-I and P14 cells in the spleen and PDLNs 5 days post-infection. TCR-I 
cells, circles (○, ●); P14 cells, squares (□, ■). WT, open symbols (○, □); TRAMP closed symbols 
(●, ■). Groups were composed of 7 WT and 8 TRAMP mice and data from one out of two 
independent experiments are shown. Horizontal lines represent mean values. 
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Fig. 4 
 
Figure 4. Tumor-specific, effector CD8+ T cells are tolerized in TRAMP mice. (A) Five million 
CD8+ TCR-I effector cells were adoptively transferred into 12-14 weeks old male TRAMP or WT 
mice that were infected 7 days later with 2 x 106 PFU rVV-I. (B) Frequency and intensity of IFN- 
production by CD8+ TCR-I cells in spleen and PDLNs are shown 5 days post-infection. (C) 
Representative examples of PD-1 surface expression of TCR-I cells at the same time point. WT, 
open circles (○); TRAMP, closed circles (●). Circles represent individual mice (n=8 per group) 
while squares (□, ■) represent the values obtained from in vitro culture of CD8+ TCR-I cells. Data 
from one out of two independent experiments are shown. Horizontal lines represent mean values. 
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Fig. 5 
 
Figure 5. Prevention of tolerance by anti-CD40 + IL-2cx + IL-12Fc. (A) One million CD8+ 
TCR-I cells were adoptively transferred into 13-16 weeks old male TRAMP or WT mice that 
received (or not) anti-CD-40 + IL-2cx + IL-12. Mice were infected 7 days after adoptive transfer 
with 2 x 106 PFU rVV-I. TCR-I cells were analyzed 5 days after infection. (B) Absolute number, 
(C) IFN- production and (D) degranulation of TCR-I CD8+ cells in spleen and PDLNs are shown 5 
days post-infection. (E) PD-1 surface expression of two representative mice is illustrated. Symbols 
represent individual mice (n=4-8 per group) and data from one out of three independent 
experiments are shown. Horizontal lines represent mean values. 
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Fig. 6 
 
Figure 6. Administration of anti-CD40 + IL-2cx + IL-12Fc improves local and systemic 
tumor-specific immunity. One million naïve TCR-I cells were adoptively transferred into 16-18 
weeks old male TRAMP mice. (A) Treatment schedule for the prevention of tolerance induction in 
TCR-I cells. (B) Frequency and intensity of IFN- production by TCR-I cells. (C) Treatment 
schedule to investigate the rescue of tolerized TCR-I cells. (D) Frequency and intensity of IFN- 
production by TCR-I cells in the spleen, PDLNs and prostate of TRAMP mice. (E) Treatment 
schedule to examine sustained responses by TCR-I cells. (F) Frequency and intensity of IFN- 
production by TCR-I cells. (G) Weight of the genitourinary tract (seminal vesicles + prostate gland 
only) at the endpoint of the experiment assessing sustained responses. (H) Weight in grams on day 
21 of dissected prostate gland. Symbols represent individual TRAMP mice and data from three out 
of seven independent experiments are shown. Horizontal lines represent mean values. 
 
  
40 
 
Fig. 7 
 
Figure 7. Administration of anti-CD40 + IL-2cx + IL-12Fc improves endogenous tumor-
specific immunity. Endogenous CD8+ CD45.1- cells were analyzed following the experimental 
designs described in figures 6A and 6D. Cells were stimulated for 5 hours in presence of a 
combination of three different SV40LT-derived peptides. (A) Frequency of IFN- production by 
endogenous CD8+ T cells at different time points after treatment. (B) Absolute number and (C) 
surface PD-1 expression of endogenous CD8+ CD45.1- cells. (D) Ratio of absolute number of CD8+ 
CD45.1- cells to FoxP3+ CD4+ Treg cells. (E) Absolute number of FoxP3+ CD4+ Treg cells in the 
prostate. Symbols represent individual TRAMP mice and data from one out of two independent 
experiments are shown. Statistics were made by one-way ANOVA and Tukey-Kramer post-test to 
compare all pairs per organ. Horizontal lines represent mean values.  
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Fig. 8 
 
Figure 8. Administration of anti-CD40 + IL-2cx + IL-12Fc has clinical efficacy in late-stage 
cancer. (A) Treatment schedule for TRAMP mice. (B) Tumor-free survival of TRAMP mice. 
Event: tumor of ≥ 1 cm3. (C) Overall survival of TRAMP mice receiving different treatments. The 
event is defined as one out of 5 following criterias: lack of escape behavior, poor general condition, 
hunched back, ruffled fur or abdominal distension. (D) Frequency of IFN- and CD107-positive 
TCR-I cells 6 months after adoptive transfer in treated animals. (E) Experimental design for late-
stage treatment of subcutaneous B16 melanoma. Event: tumor size reaching 150 mm2 (length x 
width). (F) Kaplan-Meier survival analysis of mice injected with B16F10 tumors. (G) Kaplan-
Meier survival analysis of mice bearing B16F10-OVA tumors, some of which received one million 
naïve OT-I CD8+ cells. (H) Pictures on day 99 of two out of three cured mice showing 
depigmentation at the site of the rejected tumor. Gray shades on graphs illustrate the 7 days 
treatment course. TRAMP survival analysis was performed once (n=11-14 mice per group). Data 
from two out of four experiments are shown for the subcutaneous models (n=7 mice per group). 
Log-rank (Mantel-Cox) statistical tests were performed between pairs as described. 
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6.1.6. Supplementary Materials and Methods 
Mice 
TRAMP on a pure C57BL/6 background (18) and 416Tev/J (19) mice were purchased from the 
Jackson Laboratory. P14 mice (47) and OT-I mice (48) were obtained from the Laboratory Animal 
Service Center (University of Zurich). C57BL/6JOlaHsd mice were obtained from Harlan 
Laboratories. 416Tev/J mice carry a rearranged TCR (TCR-I) specific for the H2-Db-restricted 
SV40LT epitope I (aa 206-215). P14 mice carry a rearranged TCR specific for a H2-Db-restricted 
epitope derived from amino acids 33-41 of lymphocytic choriomeningitis virus glycoprotein 
(LCMV gp). OT-I mice carry a rearranged TCR specific for a H2-Kb-restricted epitope derived 
from amino acids 257-264 of ovalbumin (OVA). TRAMP females were maintained homozygous 
and bred with C57BL/6 males to generate heterozygous TRAMP males for experiments. Age- and 
sex-matched non-transgenic littermates or C57BL/6 were used as WT controls. TCR transgenic 
mice were maintained heterozygous and bred to carry the congenic marker CD45.1 (Ly5.1). All 
mice were kept under specific pathogen-free conditions in the facilities of the Institute of 
Laboratory Animal Science (University Hospital Zurich) and had access to standard chow (Provimi 
Kliba Cat.No. 3436) and water ad lib. Experiments were performed in accordance with the Swiss 
federal and cantonal regulations on animal protection and were approved by the Swiss cantonal 
veterinary office (Zurich). 
 
Tumor models 
TRAMP mice carry the oncogenic SV40 large T antigen (SV40LT) as a transgene under the control 
of the hormone-dependent, prostate-specific rat probasin promoter, resulting in the development of 
progressive prostate cancer in male mice. At 8 weeks of age, 100% of mice have prostatic 
intraepithelial neoplasia. By 12 weeks of age, all mice have adenocarcinomas which progresses 
gradually to large poorly differentiated tumors. Metastases occur in TRAMP mice with an incidence 
of ~50% by 24 weeks of age (22). For survival experiments, body weight measurements and 
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abdominal pelvic palpations were performed every 1-2 weeks from the age of 20 weeks. Mice with 
palpable tumors at 20 weeks were excluded from the study. The event in tumor-free survival was 
defined as the detection of a tumor >1 cm3 by palpation. Death event for overall survival was 
defined as at least one out of five of the following termination criteria: lack of escape behavior, poor 
general condition, hunched back, ruffled fur or abdominal distension. B16F10 melanoma cells 
(ATCC CRL-6475) and B16F10-OVA (B16F10 stably transfected to express chicken ovalbumin as 
neo-antigen), kindly provided by Melody Swartz, EPFL, Lausanne, Switzerland, were cultured in 
Dulbecco's modified Eagle's medium (GIBCO Invitrogen) supplemented with 10% fetal calf serum, 
0.1 mM 2-mercaptoethanol, 2 mM L-glutamine and antibiotics. To establish syngeneic tumors, 2 x 
105 cells were injected s.c. in 100 μL PBS. Tumors were measured with a caliper every 2-3 days in 
two dimensions (length and width) and a death event was defined as tumor size reaching 150 mm2 
(length x width). Mice were randomized in order to have equal average tumor size and minimal 
standard deviation differences between groups on the day before starting therapy.  
 
Adoptive Transfer of CD8+ T cells 
CD8+ cells were isolated from spleens of TCR-I or P14 TCR transgenic mice by positive selection 
using CD8 MicroBeads according to manufacturer’s protocol (Miltenyi Biotec). To track cell 
divisions, CD8+ T cells were incubated for 10 minutes at 37ºC with 1 µM carboxyfluorescein 
diacetate succinimidyl ester (CFSE) (Sigma-Aldrich) in PBS, washed with media containing 10% 
fetal bovine serum (Gibco) and resuspended in PBS before injection. To generate effector CD8+ T 
cells, CD8+ cells were cultured for 3 days in RPMI-1640 supplemented with 1x MEM non-
essential amino acids, 10 mM HEPES, 50 U/mL penicillin, 50 µg/mL streptomycin, 2 mM L-
glutamine, 10% fetal bovine serum and 0.1 mM 2-mercaptoethanol (Gibco) in the presence of 
Dynabeads® Mouse T-Activator CD3/CD28 (Life technologies) with a bead-to-cell ratio of 1:1 and 
recombinant murine cytokines as follows: 60 IU/ml IL-2, 1 ng/mL IL-7, 10 ng/mL IL-15 and 10 
44 
 
ng/mL IL-21 (Peprotech). Unless otherwise stated, each mouse received 106 CD8+ T cells by i.v. 
tail vein injection. 
 
Treatment of tumor-bearing mice 
The following monoclonal antibodies were used for treatment of TRAMP mice: anti-CD40 
(FGK45), anti-CTLA-4 (UC10-4F10-11) and anti-PD-1 (RMP1-14). Antibodies were purified from 
culture supernatant using protein G sepharose 4 Fast Flow (GE Healthcare) columns according to 
manufacturer’s protocol. Antibodies were administered at 50 µg (anti-CD40) or 250 µg (all others) 
in 200 µl PBS. IL-2/anti-IL-2 complexes were prepared with the S4B6 mAb as described (29) and 
an equivalent of 15000 units of recombinant mouse IL-2 (eBioscience) was used per injection. 
Recombinant mouse IL-12Fc was produced as described (49) and bioactivity was quantified by an 
IFN- secretion assay with ConA-stimulated splenocytes as previously described (50) using the 
following formula: specific activity (units/mg) = 106 / ED50 (ng/ml). IL-12Fc was administered in 
PBS at 10000 units/kg per i.p. injection for TRAMP mice or 100 units/kg per i.t. injection for 
subcutaneous models. All other substances were injected i.p. at time points indicated in the figures. 
 
Generation of recombinant vaccinia virus and infection 
Vaccinia virus (VV), strain WR, was originally obtained from Dr. B. Moss (National Institutes of 
Health, Bethesda, MD, USA). Recombinant VV carrying LCMV gp (rVV-G2) was originally 
obtained from Dr. D. Bishop (Institute of Virology, Oxford, UK). Recombinant VV expressing the 
SV40LT epitope epitope I (aa 206-215) was generated as previously described (51). Briefly, the 
vector pSC11.30R.2 (52) was digested with the restriction enzymes NcoI and BglII. Two 
oligonucleotides were annealed (Fwd: 5’-CAT GTC CGC CAT CAA CAA TTA CGC CCA GAA 
GCT GTA-3’, Rev: 5’-GAT CTA CAG CTT CTG GGC GTA ATT GTT GAT GGC GGA-3’) and 
directly ligated to the digested pSC11.30R.2. This transfer vector was then used to generate a 
recombinant vaccinia virus coding for SV40LT206-215 through homologous recombination at the 
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thymidine kinase locus during concomitant transfection and infection of human thymidine kinase 
deficient 143B cell line (ATCC CRL-8303) with VV WR. Recombinant viruses were selected using 
5-bromo-2’-deoxyuridine (BrdU) and recombinant plaques were identified by -galactosidase 
activity as previously described (53). Recombinant VV were plaque purified three times on BSC40 
cells (ATCC CRL-2761). Viral titers were determined by the same method. All VV were 
propagated on BSC40 cells at a multiplicity of infection of 0.1. For infections, mice received 2 x 
106 plaque-forming units i.p. 
 
Peptides 
SV40LT206-215 (SAINNYAQKL), SV40LT223-231 (CKGVNKEYL), SV40LT404-411 (VVYDFLKC) 
and LCMV gp33-41 (KAVYNFATC) were purchased from PolyPeptide Laboratories in 
immunograde quality. Stocks of 10 mM were prepared in DMSO and stored at -20°C. 
 
Flow cytometry 
To obtain single-cell suspensions, spleens and lymph nodes were mechanically homogenized with a 
syringe plunger on a sterile filter. Prostates were cut into small pieces and digested for 1 hour at 
37ºC with agitation in RPMI containing 1 mg/ml collagenase IV and 2.6 µg/ml (6 U/ml) DNase I 
(Sigma-Aldrich), washed once with RPMI followed by filtration through 40 µm cell strainer. For 
subsequent staining of surface markers, cells were washed and resuspended in PBS and stained for 
20 min at room temperature with panels of fluorochrome-labeled antibodies. To detect intracellular 
IFN-, cells were restimulated for 5 hours at 37ºC with 10 µM of the relevant peptide in presence of 
10 µg/ml brefeldin A (Sigma-Aldrich). In some cases, 2.5 µg/ml of FITC anti-mouse CD107a 
(clone 1D4B, BioLegend) was added during restimulation allowing detection of degranulation. 
After 5 hours, cells were washed in PBS followed by surface staining for 20 minutes at room 
temperature, washed again and fixed with 4% paraformaldehyde in PBS. Cells were washed with 
permeabilization buffer (20 mM EDTA + 2% FBS + 0.03% NaN3 + 0.1% saponin in PBS). Samples 
46 
 
were incubated overnight at 4ºC with APC anti-mouse IFN- (clone XMG1.2, BioLegend). For 
staining of regulatory T cells (Treg), APC anti-mouse FoxP3 (clone FJK-16s) and the Foxp3 
Transcription Factor Staining Buffer Set (eBioscience) were used according to manufacturer’s 
protocol. Unless otherwise stated, the following antibodies were purchased from BioLegend: anti-
CD45.1 (A20), anti-CD45.2 (104), anti-CD8 (53-6.7), anti-CD8 (53-5.8), anti-TCR V7 
(TR310), anti-TCR V2 (B20.1, Becton Dickinson), anti-CD4 (RM4-5), anti-CD25 (PC61), anti-
PD-1 (RMP1-30 and 29F.1A12). Doublets were excluded based on linear and area values of the 
forward scatter. Dead cells were excluded using the live/dead® Fixable Violet Dead Cell Stain Kit 
(Life technologies). The detailed gating strategies are illustrated in Figure S8. Absolute counts were 
determined with CountBright™ Absolute Counting Beads from Life Technologies and used to 
calculate CD8+ to Treg (CD4+ FoxP3+) ratios. Samples were measured using a CyAn ADP 9 flow 
cytometer (Beckman Coulter) and analyzed with FlowJo v7.6.5 software (Tree Star).  
 
Statistical analysis 
Statistical analyses were performed with GraphPad Prism version 5.03 (GraphPad Software, Inc). 
For comparisons, unless otherwise stated, unpaired, two-tailed Student’s t tests with systematic 
Welch’s correction were done with an alpha of 0.05. For comparison of more than 2 experimental 
groups, one-way ANOVA either with Tukey-Kramer’s post-test was used to compare all pairs or 
Dunnett’s post-test to compare all groups to the control as mentioned in figure legends. A log-rank 
test (Mantel-Cox) was used for Kaplan-Meier survival curves comparison between selected pairs. 
P-values < 0.05 were considered statistically significant and marked with asterisks (*, P < 0.05; **, 
P < 0.01; ***, P < 0.001). In Figure S2, two outliers identified with a significant Grubb’s test (alpha 
0.05) with the online tool (http://graphpad.com/quickcalcs/Grubbs1.cfm) are shown in the bar 
graph, but were excluded from statistical analysis. 
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6.1.7. Supplemental Figures and Legends 
Fig. S1.  
 
Figure S1. Tolerization of TCR-I cells in TRAMP mice 
One million CD8+ TCR-I cells were adoptively transferred into 14-17 weeks old male TRAMP or 
WT mice. Mice were infected 7 days after adoptive transfer with 2 x 106 PFU rVV-I. TCR-I cells 
were analyzed 5 days after infection. (A, G) Absolute number of TCR-I cells and (B, H) of IFN- 
producing TCR-I cells are shown for the spleen and PDLNs respectively. (C, I) Frequency and (D, 
J) intensity of IFN- production of transferred cells are illustrated. (E, K) Frequency of 
degranulating TCR-I CD8+ cells in spleen and PDLNs are shown 5 days post-infection. (F, L) 
GMFI of PD-1 surface expression is displayed. Symbols represent individual mice (n=8 per group) 
and data from one out of three independent experiments are shown. Horizontal lines represent mean 
values. 
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Fig. S2.  
 
Figure S2. Preventing tolerance induction by immune intervention. One million CD8+ TCR-I cells were adoptively transferred into 13-17 weeks 
old male TRAMP or WT mice. Mice were treated as described in Figure 5A and infected 7 days after adoptive transfer with 2 x 106 PFU rVV-I. (A) 
Equation used for the normalization of data to enable comparison between experiments. (B) Equation used for the normalization of PD-1 expression 
data. Normalization was performed to have WT responses averaging 100% and 0% for TG controls for all read-outs. (C) Normalized responses 
obtained from 14 different immunotherapies for 6 TCR-I read-outs in the spleen. Each bar represents a read-out as illustrated in the legend. Data are 
represented as mean ± SD. Two outliers identified by a significant Grubb’s test were excluded from the calculations but are shown on the bar graph as 
circles (●).  
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Fig. S3.  
 
Figure S3. Administration of anti-CD40 + IL-2 complexes + IL-12Fc improves local and 
systemic tumor-specific immunity. One million naïve TCR-I cells were adoptively transferred into 
16-18 weeks old male TRAMP mice. (A, C, E) Absolute numbers of TCR-I cells in the spleen, 
PDLNs and prostate of TRAMP mice at respective endpoints. (B, D, F) Surface PD-1 expression on 
TCR-I cells in TRAMP mice. Two representative mice are shown per panel. Panels are related to 
the treatment schedules in Figure 6 as follow: panels A-B (Figure 6A), panels C-D (Figure 6C) and 
panels E-F (Figure 6E). Symbols represent individual TRAMP mice and data from three out of 
seven independent experiments are shown. Horizontal lines represent mean values. 
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Fig. S4.  
 
Figure S4. Immune interventions can shift the balance from tolerance into priming of tumor-
specific immunity. One million naïve TCR-I cells were adoptively transferred into 14-17 weeks old 
male TRAMP mice. Treatment schedule was identical to Figure 6A. (A) Absolute number of TCR-I 
and (B) of IFN-+ TCR-I cells in the prostate on day 7 after transfer. (C) Frequency and (D) 
intensity of IFN- production by TCR-I cells. (E) Frequency of degranulating and (F) PD-1 surface 
expression of transferred CD8+ cells. Symbols represent individual mice and data from one out of 
two independent experiments are shown. Significant differences were determined using one-way 
ANOVA with Dunnett’s post-test to compare all groups to the control group. Horizontal lines 
represent mean values.  
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Fig. S5.  
 
Figure S5. Inverse correlation between PD-1 surface expression level and IFN- production by 
IFN-+ TCR-I cells. One million naïve TCR-I cells were adoptively transferred into 16-18 weeks 
old male TRAMP mice. Multiple groups were treated as in Figures 6A, 6D and 6G. Logarithmic 
transformation of PD-1 GMFI and IFN- GMFI gated on IFN-+ TCR-I cells were plotted for the 
(A) spleen, (B) PDLNs and (C) prostate. Linear regressions were performed in GraphPad Prism. 
Samples with less than 20 IFN-+ TCR-I cells were excluded from the correlation analysis. Mice 
were processed 7 or 21 days after adoptive transfer to cover a wider range of responsiveness. All 
samples were measured on the same day. Symbols represent individual TRAMP mice.  
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Fig. S6.  
 
Figure S6. Immune interventions trigger tumor-specific endogenous CD8+ T cell responses. 
Mice from Figure S4 were analyzed for endogenous CD8+ T cells. Treatment schedule is depicted 
in Figure 6A. (A) Absolute number of endogenous CD8+ T cells in the prostate 7 days after the start 
of therapy. (B) Absolute number of IFN-+ endogenous CD8+ T cells. (C) Frequency and (D) 
intensity of IFN- production by these cells. (E) Frequency of CD107a+ and (F) PD-1 surface 
expression of endogenous CD8+ T cells. Symbols represent individual mice and data from one out 
of two independent experiments are shown. Significant differences were determined using one-way 
ANOVA with Dunnett’s post-test to compare all groups to the control group. Horizontal lines 
represent mean values.  
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Fig. S7.  
 
Figure S7. Tumor growth curves of subcutaneous B16 melanoma. Experimental design is 
described in Figure 8. (A) B16F10 tumor growth in C57BL/6 mice. (B) B16F10-OVA tumor 
growth in C57BL/6 mice, some of which received one million naïve OT-I CD8+ cells on day 13. 
Gray shades on graphs mark the 7 days treatment with anti-CD40 + IL-2 complexes + IL-12Fc. 
Dotted line represents the cutoff considered as death event for survival analysis. Data from two out 
of four experiments are shown. 
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Fig. S8.  
 
 
Figure S8. Gating strategy for flow cytometry analysis. Two representative examples of murine 
prostates are shown. (A) Gating strategy for CD8+ endogenous and adoptively transferred TCR-I 
cells showing exclusion of beads, doublets and dead cells. In all experiments, counting beads were 
separated from cells by gating on bright events in 2 unused channels. Following gating was 
performed on live CD8+ cells followed by CD45.1 discrimination. Representative example of IFN-
, CD107a and PD-1 stainings are shown. (B) Identification of T regulatory cells was done by 
exclusion of beads and doublets as in (A) followed by gating on live CD45.2+, CD4+ and FoxP3+ 
cells. CD25 was included in the staining but not considered for Treg discrimination.  
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6.1.8. Supplemental Tables 
Table S1. Impact of various immune interventions on preventing tolerance while improving proliferation and function of TCR-I cells  
(Data for spleen).  
Treatment Abs. countTCR-I 
% IFN-+
of TCR-I 
GMFI IFN- 
of IFN-+ TCR-I
% CD107a+ 
of TCR-I 
GMFI PD-1
of TCR-I 
Abs. count 
IFN-+ TCR-I 
IL-2cx + IL-12Fc + aCD40 75 72 53 90 150 63 
IL-2cx + aCD40 9 74 49 92 144 13 
aCTLA4 + aPD1 + aCD40 94 14 18 33 134 34 
IL-12Fc + aCD40 44 35 1 60 132 26 
aCD40 53 31 17 47 115 26 
IL-12Fc + aPD1 + aCTLA4 47 7 -21 38 113 33 
IL-2cx + aPD1 + aCTLA4 2 17 -3 47 115 2 
aPD1 11 2 -15 20 84 3 
aPD1 + aCTLA4 N/A 10 -6 N/A 60 N/A 
IL-12Fc + aCTLA4 9 -12 -24 -10 84 1 
IL-2cx -6 6 -27 -9 116 -2 
IL2cx + IL12Fc -7 1 -9 2 100 -2 
IL12Fc -6 5 5 14 31 12 
aCTLA4 3 0 -15 21 30 1 
Tables S1, S2 and S3, Related to Figures 5 and S2. Impact of various immune interventions on preventing tolerance while improving 
proliferation and function of TCR-I cells. Exhaustive compilation of all normalized data (see formulas in Figure S2) obtained with spleen (Table S1) 
and PDLNs (Table S2) of treated mice. Treatments are ranked by global average of all spleen and PDLNs values and the 95% confidence interval for 
this average is shown (Table S3). The 3 best responses per read-out per organ are highlighted in gray. Absolute counts of TCR-I cells and counts of 
IFN-+ TCR-I in PDLNs were excluded from calculations since no significant differences were observed between WT and TG control mice (Figures 
S1G and S1H). Two outliers identified by a significant Grubb’s test shown in Figure S2 were also excluded from the calculations. 
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Table S2. Impact of various immune interventions on preventing tolerance while improving proliferation and function of TCR-I cells  
(Data for PDLNs).  
Treatment % IFN-+of TCR-I 
GMFI IFN- 
of IFN-+ TCR-I
% CD107a+
of TCR-I 
GMFI PD-1
of TCR-I 
IL-2cx + IL-12Fc + aCD40 94 121 86 115 
IL-2cx + aCD40 56 88 43 109 
aCTLA4 + aPD1 + aCD40 40 16 84 94 
IL-12Fc + aCD40 55 48 67 82 
aCD40 29 -5 54 87 
IL-12Fc + aPD1 + aCTLA4 40 24 52 78 
IL-2cx + aPD1 + aCTLA4 2 -22 7 86 
aPD1 17 15 23 65 
aPD1 + aCTLA4 14 9 N/A 44 
IL-12Fc + aCTLA4 18 -4 24 49 
IL-2cx -2 -25 -28 95 
IL2cx + IL12Fc 7 -30 -4 47 
IL12Fc 18 -26 17 -13 
aCTLA4 -8 -30 -11 6 
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Table S3. Impact of various immune interventions on preventing tolerance while improving proliferation and function of TCR-I cells 
(Average of spleen and PDLNs data).  
  95% Confidence Interval 
Treatment Global Average Lower Limit Higher Limit
IL-2cx + IL-12Fc + aCD40 92 81 103 
IL-2cx + aCD40 68 54 82 
aCTLA4 + aPD1 + aCD40 56 43 70 
IL-12Fc + aCD40 55 44 65 
aCD40 45 33 57 
IL-12Fc + aPD1 + aCTLA4 41 29 53 
IL-2cx + aPD1 + aCTLA4 25 11 40 
aPD1 23 13 32 
aPD1 + aCTLA4 22 12 31 
IL-12Fc + aCTLA4 13 3 24 
IL-2cx 12 -5 28 
IL2cx + IL12Fc 11 -3 24 
IL12Fc 6 -3 14 
aCTLA4 0 -7 6 
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6.2. Generation of a new transgenic mouse model (ARTURO) 
6.2.1. Introduction  
Simian virus 40 expresses the dominant acting oncoprotein large T antigen (SV40LT) that 
elicits cellular transformation mostly by associating with key cellular proteins and altering the 
signaling pathways of the tumor suppressors p53 and Rb-family (102). Several reasons argue for the 
use of SV40LT-based models for the investigation of the interplay between tumors and tumor-
specific immunity: (i) SV40LT expression results in reliable tumor induction, independent of the 
tissue (103-107), (ii) in contrast with transplanted tumor cell lines, SV40LT-tumors are an accepted 
model for spontaneous tumors with a relatively slow genesis and the presence of a relevant tumor 
microenvironment (93, 108-111), (iii) several H-2b-restricted T cell epitopes have been identified in 
SV40LT, allowing precise dissection of SV40LT-specific immunity during tumorigenesis (112, 
113).  
To generate a new transgenic mouse model that allows the induction of tumors in a tissue of 
interest, we targeted a conditional transgene cassette to the well-characterized Rosa26 euchromatic 
locus by homologous recombination in mouse embryonic stem cells (mES cells). Targeting the 
transgene to the Rosa26 locus results in reliable transgene expression and minimizes the risk of an 
unwanted phenotype due to random integration as observed after a conventional transgenic 
approach (114). The targeting construct was designed to achieve homologous recombination at the 
target locus to replace native Rosa26 locus sequences with a large transgene cassette as depicted in 
Figure 10. The 5’ short and 3’ long homology arms (SA and LA) in bright pink consist of several 
kilobases identical to the C57BL/6 Rosa26 locus enabling the cell’s DNA repair machinery to 
substitute wild-type DNA for the transgenic cassette through homologous recombination (115).  
The targeting construct contained a loxP-flanked stop cassette downstream of a ubiquitous 
promoter (CAG). The CAG promoter consists of a CMV enhancer sequence, the chicken -actin 
promoter and the splice acceptor of the rabbit -globin gene, which allows strong gene expression 
in mammalian cells (116). The floxed-stop cassette contains sequences to block ubiquitous 
expression of the transgenes while also including the sequence coding for neomycin to facilitate 
selection of targeted mES clones (115, 117).  
The vector was modified to introduce the transgenes downstream of the stop cassette (Figure 
10) to enable conditional expression in double-transgenic offspring when crossing ARTURO mice 
with tissue-specific CreERT-expressing mice (115, 117-119). CreERT is a fusion protein between the 
Cre recombinase that mediates floxed sequence excision and the mutated hormone-binding domain 
of the human estrogen receptor (ERT) (120). In absence of tamoxifen, the synthetic ligand for ERT, 
the Cre recombinase is associated with heat shock proteins, which inhibit translocation of Cre into 
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the nucleus. After association of ERT with its ligand, Cre can translocate into the nucleus and 
remove loxP-flanked nucleotides.  
The expression cassette of our targeting construct contains the SV40LT to drive 
carcinogenesis, the firefly luciferase to enable non-invasive monitoring of arising tumors and 
metastases by luminescence with an IVIS imaging system (121, 122) and enhanced green 
fluorescent protein (eGFP) to enable identification of tumor cells by flow cytometry. Thus, double-
transgenic ARTURO x TS-CreERT mice should only express the transgenes in a tissue of choice 
after injection of tamoxifen, which will result in tumor development of this particular tissue. By 
comparing fundamentally different target tissues, we aimed to find mechanisms that preclude 
immune-mediated tumor control that are active in every malignancy and some that are organ-
specific. In fact, there is growing evidence that the complexity of the immune infiltrate is influenced 
by the tissue where the tumor originates and the stage of malignancy, as observed by the analysis of 
distinct tumors by flow cytometry (123). These variations suggest that the tumor milieu may differ 
significantly between primary and metastatic lesions. Since the immune networking in tumors is of 
high functional and clinical relevance (35, 36), it is important to consider these qualitative and 
quantitative differences in the tumor microenvironment for immune-based therapies. For example, 
immunotherapies that rely on antibody-dependent cell-mediated cytotoxicity (ADCC) may require a 
subset of cells with a specific FcγR at the tumor site for their efficacy (124-127). 
  
Figure 10. Schematic strategy for targeting and screening of mouse ES cells. 
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Figure 11. Schematic description for the induction of tissue-specific tumorigenesis in double-
transgenic mice. 
 
6.2.2. Material and methods 
6.2.2.1. Cloning of targeting construct 
A targeting construct (BBV43GFP-GatewayMod) containing homology arms for the 
Rosa26-locus (SA and LA), a loxP-flanked stop cassette downstream of the CAG promoter, a 
polylinker including gateway recombination cloning sites (attR1 and attR2) and the IRES-eGFP-pA 
cassette was kindly provided to us by Sergio Haller (Institute for Experimental Immunology, 
University of Zurich). For the cloning, SV40LT was digested (EcoR1 + Xba1) and gel-purified 
from the template vector pBS-Tag(wt). The purified fragment was ligated upstream of the IRES-
Luc cassette in the linearized (Nhe1 + EcoR1) pGL3-Basic luciferase reporter vector. Subsequently, 
the SV40LT-IRES-Luc cassette was PCR amplified with the following primers: 5’-TTT TGT CGA 
CGC CGC CAC CAT GGA TAA AGT TTT AAA CAG-3’ and 5’-TTT TGC GGC CGC TTA 
CAC GGC GAT CTT TCC-3’. The purified PCR product was cloned (Sal1 + Not1) into the 
gateway pENTR11 dual selection entry vector. Gateway recombination (Gateway LR Clonase, Life 
Technologies) was performed between the vectors pENTR11-SV40LT-IRES-Luc (entry clone with 
attL sites) and BBV43GFP-GatewayMod (destination vector with attR sites) according to 
manufacturer’s protocol. The recombined DNA mixture was electroporated into SURE 
electroporation-competent E. coli cells (Stratagene) to avoid rearrangement and deletion of non-
standard secondary and tertiary structures that occur frequently in eukaryotic DNA. Although 
SURE cells were used, abnormal rearrangements could only be prevented by incubating SURE cells 
at 25°C instead of 37°C. All enzymes were purchased from New England Biolabs unless otherwise 
stated. 
 
6.2.2.2. Generation and identification of targeted ES cell 
Amplification, linearization (SgrD1) and purification of the targeting construct was 
performed and shipped to the Transgenics & Gene Targeting Facility at the Alexander Fleming 
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Biomedical Sciences Research Center in Vari, Greece. The targeting service was done by 
electroporating the linearized construct into Bruce-4 murine embryonic stem cells (128). Neomycin 
selection was used to isolate transgenic ES cell clones. Cells were expanded in 96-well plates and 
the frozen pellets were transferred back in Zurich for the identification of clones with single and 
proper integration at the Rosa26 locus. Southern blotting was carried like previously published 
(115, 119) using 3 different radio-labeled probes (P1, P2 and P3 in Figure 10). Briefly, genomic 
DNA was extracted, digested with EcoR1, migrated on 0.7% agarose gel and followed by alkaline 
transfer onto Zeta-Probe cationized nylon membrane (Bio-Rad). Radioactive labeling of probes was 
performed with [α-32P]-dCTP using the Takara Ladderman labeling kit. Overnight hybridization of 
membranes with the probes was done at 65ºC in a rotating incubator. After multiple washing steps, 
binding of probes was detected with a PhosPhor screen (GE Healthcare) and digitized using a 
phosphor imaging system. 
 
6.2.2.3. Generation of transgenic line 
Following the identification of multiple targeted ES cell clones, 5 clones were expanded and 
karyotyped by the Transgenics & Gene Targeting Facility in Greece. Selected clones were used for 
blastocysts injections and transferred into C57xCBA foster mice to generate chimeric mice (see 
Figure 14). Chimeras were bred to C57BL/6J-Tyrc-2J (albino) mice and the progeny was genotyped 
for the presence of the transgene. 
 
6.2.2.4. Genotyping of progeny 
Genotyping of pups was performed by multiple PCRs enabling identification of the targeted-
locus (Rosa26 PCRs) or simply the presence of transgene (SV40LT). Reactions with FIREPol DNA 
Polymerase (Solis BioDyne) were performed according to manufacturer’s instructions using the 
primers in Table 2. Genomic DNA was extracted from mouse tissues with the rapid NaOH lysis as 
reported previously (129). 
Primer Sequence (5’→3’) Binding Pairing Amplicon (bp) 
AB102 TTT GCC AGG TGG GTT AAA GGA GCA SV40LT AB103 See below 
AB103 CAG CAG AGC CTG TAG AAC CAA ACA SV40LT AB102 WT = N/A TG = 400 
AB106 AAA GTC GCT CTG AGT TGT TAT Rosa26  (5’ SA) 
AB107 and 
AB108 
See 
below 
AB107 GGA GCG GGA GAA ATG GAT ATG Rosa26  (3’ LA) AB106 
WT = 600 
TG = N/A 
AB108 CAT CAA GGA AAC CCT GGA CTA CTG CAG promoter AB106 
WT = N/A 
TG = 241 
Table 2. Primers for PCR genotyping of chimeras and progeny. 
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6.2.3. Results 
6.2.3.1. Targeting of murine embryonic stem cells 
Following the cloning and sequencing of the targeting construct, the purified vector was 
linearized and sent to the Transgenics & Gene Targeting Facility at the Alexander Fleming 
Biomedical Sciences Research Center in Vari, Greece. Targeting was performed in Bruce-4 ES 
cells, one of the most widely used C57BL/6 ES cell line for their high targeting efficiency and 
proven germ line transmission (Figure 12) (128). The targeting construct was transferred by 
electroporation and 384 neomycin-resistant ES cell clones were isolated. 
 
Figure 12. Gene targeting of embryonic stem cells. Figure from Annika Röhl, www.partners.org 
 
Identification of clones with correct integration was determined by southern blotting of 
EcoRI-digested genomic DNA (gDNA). Three probes were used, P1 and P2 to assess integrity at 
both ends of the insertion and P3, an internal probe, to confirm single integration event (Figure 10). 
Targeting efficiency was 14% with a total of 54 clones with expected southern blot patterns (data 
not shown). Five targeted clones (A5, B8, D8, F12 and G9) and two neomycin-resistant non-
targeted controls (C2 and C4) were selected for expansion and confirmation of southern blots 
(Figure 13). Random integration for C2 and C4 is illustrated by the absence of transgenic (TG) 
bands for P1 and P2 while P3 detects a fragment of inappropriate size. 
 
Figure 13. Southern blot confirmation of proper integration of the transgene into the Rosa26 locus. 
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6.2.3.2. Generation and breeding of chimeras 
Subsequently, ES cell clones were injected into albino blastocysts and transferred to foster 
mice (Figure 14). Albino blastocysts were used to allow visual discrimination of chimeric mice 
since transgenic Bruce-4 ES cells lead to development of black and white fur while non-chimeric 
mice remain albino. The 216 blastocysts injections at the Transgenics & Gene Targeting Facility in 
Greece generated a total of 36 pups, of which 17% (6 / 36) were chimeric. One chimera died 
unexpectedly before sexual maturity. Figure 15 shows the five other chimeras and some albino 
pups. Breedings between albino mice and these five chimeras were performed and are summarized 
in Table 3. 
 
Figure 14. Generation of gene targeted mice. Figure from Annika Röhl, www.partners.org 
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Figure 15. Chimeras obtained after injection of targeted ES cells into blastocysts.  
 
 Chimera 1 Chimera 2 Chimera 3 Chimera 4 Chimera 5 Chimera 6
Sex Male Female Female Male Male Male 
Mouse ID B-D8-1M B-D8-2F B-D8-3F B-A5-4M B-A5-5M B-G9-6M 
Litters produced 2 2 0 3 3 3 
Total pups 14 10 0 62 
# of black pups 0 0 0 10 
# of transgenic  
black pups 
0 0 0 0 
Table 3. Summary of breedings of chimeric mice with albino mice. 
 
Based on the results of the breedings and genotyping shown in Table 3 and Figure 16, no 
transgenic pups in the chimeras’ progeny could be identified. Chimeras were then sacrificed and 
biopsies were taken from a chimera producing black pups. PCR genotyping was performed on this 
chimera’s samples to confirm the presence of the transgene in the reproductive tract. Surprisingly, 
genotyping revealed the lack of the transgene in all samples tested (Figure 17). 
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Figure 16. PCR genotyping of black progeny.  
 
Figure 17. PCR genotyping of chimera 5.  
 
6.2.4. Discussion and outlook 
Germline transmission of the transgene was not achieved so far. The southern blots proved 
that the ES cells were successfully targeted, but the fact that all tissues from chimera 5 were 
negative for the transgene may explain the lack of germline transmission.  
Currently, we don’t know why the tissues from chimera 5 were transgene-negative. One 
possibility might be that the ES cell clone used for injection did not represent a pure population and 
some aberrant cells overgrew the transgenic ES cells during in vitro expansion or following 
injection. Toxicity of the transgene can’t be excluded, but the conditional nature of the construct 
should in theory protect from toxicity in absence of Cre recombination. In fact, around half of the 
black pups died early after birth, which may support developmental toxicity of the transgene. 
However, considering the absence of the transgene in the chimera and the fact that albino progeny 
also had a high mortality rate precludes any conclusions. 
Another possibility that could explain the absence of the transgene in chimera 5 is transgene 
instability. The integrated portion of the construct (15 kb) contained multiple repeated regions that 
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may increase genomic instability. It is conceivable that the absence of neomycin selection increases 
the possibility of disruption at the Rosa26 locus. Sequencing of the Rosa26 locus of the chimeras or 
southern blotting could provide data to better understand if this is happening or not. Finally, a 
human error leading to the use of the wrong clone for injection could explain transgene-free 
chimeras. 
Ultimately, bringing this project to completion requires the generation of more chimeras, 
including southern blot reconfirmations of the targeted clones to use for blastocysts injections and 
successful outcome is not guaranteed.  
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7. Discussion 
Immunotherapy has come a long way since the first reports of a relationship between 
infection and cancer regression during the 18 and 19th centuries (130, 131). Nowadays, combined 
cancer death rate has been steadily declining for over 2 decades (94) and this success can be 
partially explained by the emergence of new treatments, including modern immunotherapies. 
Currently approved immunotherapies include: cytokines (IL-2, IFN-α) (132, 133), checkpoint 
blockade antibodies (anti-CTLA-4, anti-PD-1) (134-136), cancer vaccines (Sipuleucel-T) (79), 
pattern recognition receptors agonists (imiquimod, BCG) (137, 138) and a plethora of tumor 
targeting antibodies including Bevacizumab and Rituximab to name a few (139, 140). In addition, 
there are several other approaches indicating feasibility and efficacy in humans that have not 
reached approval yet. These promising treatments undergoing clinical trials include several 
combinations of checkpoint blockade with radio- or chemotherapy (141), personalized cancer 
vaccines (142, 143) and adoptive T cell transfers (80). 
Fighting cancer with immunotherapy has multiple advantages over other treatments. First, 
immunotherapies are usually relatively well tolerated and are less toxic than aggressive 
chemotherapeutic regimens, for example in patients with decreased renal function (144). Second, 
immune modulation can result in systemic tumor-specific responses and therefore can prevent or 
control metastasis (70, 75, 145, 146). Third, such treatment can induce sustained tumor-specific 
immunity (134, 147-150). Fourth, the immune system can eliminate quiescent as well as dividing 
tumor cells while conventional treatments like radio- and chemotherapy preferentially attack 
dividing cells. Last but not least, immunotherapy shows clinical efficacy in cancer patients who are 
not responding to any other treatments (134, 151, 152).  
In order to achieve sustained clinical efficacy with cancer immunotherapy, it is necessary to 
overcome T cell dysfunction, which is a consequence of suboptimal priming and the 
immunosuppressive tumor microenvironment. Here, we described a powerful experimental strategy 
for the in vivo evaluation of interventions with respect to the improvement of tumor-specific 
immunity and prevention of tolerance induction in CD8+ T cells using a clinically relevant, 
autochthonous mouse model of prostate cancer. We identified the combination of anti-CD40 + IL-
2cx + IL-12Fc as uniquely efficacious in inducing protective, long-lasting tumor-specific immunity 
of adoptively transferred tumor-specific CD8+ T cells. This immune intervention had clinical 
efficacy in late stage preclinical cancer models including curative potential. 
Our study highlights the qualitative and quantitative importance of signals 2 and 3 in 
priming protective T cell immunity. Our findings are in line with recent evidence showing that the 
sum of intracellular inputs resulting from antigen affinity, costimulation and cytokines dictates the 
68 
 
extent of T cell expansion (59). In this elegant study, Marchingo et al. quantified the relative 
contribution of different pathways to T cell division destiny. Their data showed that different 
costimulatory molecules (CD28 and CD27) and cytokines (IL-2, IL-12) sum up linearly to impact 
on the number of mitotic cycles a T cell undergoes after activation. Moreover, this effect can be 
titrated based on the concentration of cytokines used. This work identified a quantitative basis for 
the current three-signal model of T cell activation.  
Although the combination of anti-CD40 + IL-2cx + IL-12Fc outperformed all other 
combinations we tested, it is possible that combinations of different costimulatory and cytokine 
signals represent alternative means to generate T cell responses of similar or even higher 
magnitude. Indeed, although CD27, CD28, IL-2 and IL-12 represent well-known proteins involved 
in signals 2 and 3, many more molecules contribute to the equation, including but not limited to 
those illustrated in Figure 8 of the introduction (60). This may explain in part why the combination 
of anti-CD40 + IL-2cx + IL-12Fc was so efficient compared to the other combinations we tried. 
Indeed, anti-CD40 can strongly improve the quality of priming by its capacity to license antigen-
presenting cells (153-155). Our results showed that anti-CD40 + IL-2cx + IL-12Fc supported 
differentiation of adoptively transferred CD8+ T cells into protective effectors. Moreover, this 
therapy also generated a memory pool detectable 6 months after treatment, which provided 
systemic, long-lasting cancer surveillance, probably contributing to the extended survival we 
observed. Altogether, the therapeutic enhancement of signals 2 and 3 with the resulting effects on 
adoptively transferred tumor-specific T cells provides an explanation to the efficacy of this 
treatment to treat late-stage cancer in mice. Although the mechanism of action was not investigated 
in depth, the absence of survival benefit in TRAMP mice treated with anti-CD40 + IL-2cx + IL-
12Fc without adoptive transfer strongly supports a CD8-dependent mechanism. 
Although APC maturation, costimulation and cytokines are essential to avoid tolerance 
induction in T cells, the therapeutic approach described in this thesis may neglect an important 
cause of T cell tolerance. Indeed, naïve, but also differentiated effector T cells are tolerized in the 
context of cancer, most probably due to the plethora of immunosuppressive cells and molecules in 
the tumor microenvironment. This provides the rationale for further combining immunotherapies 
with conventional or targeted approaches to disrupt the tumor milieu and shift the balance towards a 
more immunosupportive setting. Local radiotherapy might be particularly well suited for this as it 
reduces the tumor load and at the same time promotes tumor-specific immunity (61-63, 156, 157). 
Other approaches to counteract the immunosuppressive signals of the tumor microenvironment 
include the targeting of immune-checkpoint proteins, such as PD-1, LAG-3 or adenosine 2A 
receptor to name a few (83, 158).  
69 
 
The recent approval of checkpoint blockade therapy with anti-CTLA-4 to treat metastatic 
melanomas represents an important milestone in the fight against cancer (134, 149). Subsequently, 
current clinical trials aim to broaden the indications for anti-CTLA-4 (159-161). However, as seen 
in melanoma patients, the frequency of responders to ipilimumab remains relatively low yet for 
unknown reasons, which suggests that other pathways must be targeted (134, 149). Following this 
line, PD-1 blockade, which as shown higher response rates including efficacy in ipilimumab-
refractory patients and also better toxicity profile than anti-CTLA-4 (136, 162, 163), is now being 
combined with ipilimumab in humans (84). Based on these data and its approval by the Food and 
Drug Administration, anti-PD-1 (pembrolizumab) may represent a pillar for future combinations of 
immunotherapies. 
A reason that may explain the relatively low success rate of ipilimumab lays in our 
incomplete understanding of its mechanism of action. For example, it was shown following its 
FDA-approval that anti-CTLA-4 efficacy relies not only on the blockade of its target, but also on 
the selective depletion of regulatory T cells due to their high expression of CTLA-4 (125-127). This 
mechanism probably explains why anti-CTLA-4 showed low efficacy in our experimental setup. 
Indeed, we used the anti-mouse CTLA-4 (clone UC10-4F10-11), which is an Armenian hamster 
IgG1 with weak affinity to murine FcγRs and therefore doesn’t trigger ADCC. We also observed 
low efficacy with anti-PD-1 in TRAMP mice. However, in this case ADCC is not believed to be 
involved in the mechanism of action of this rat IgG2a antibody. Recent data from cancer patients 
being treated with blockade of the PD-1–PD-L1 axis indicate that PD-L1 expression in the tumor 
microenvironment correlates with better response rates (45, 46, 144). Based on this data, it is 
possible that the low efficacy of PD-1 blockade we observed in TRAMP mice is due to weak or 
absent PD-L1 expression in the tumor microenvironment (164).  
The lack of biomarkers is another cause of low response rates with checkpoint blockade 
since it impairs the clinicians’ ability to identify which patients benefit from this therapy. For 
example, recent data support the use of sequencing to establish the mutational load in melanoma 
patients for which anti-CTLA-4 treatment is being considered. In fact, higher mutational load is 
associated with a greater neoantigen landscape being presented by tumor cells and correlated with 
clinical benefit of anti-CTLA-4 immunotherapy (47). Subsequently, it is likely that the benefits of 
exome sequencing and identification of neoantigens will not be restricted to melanoma patients. 
Indeed, it is conceivable that a wider spectrum of neoantigens would correlate with clinical benefit 
in other types of cancer treated by immunomodulatory drugs.  
Besides having the potential to be used to identify biomarkers, exome sequencing provides 
an opportunity to develop therapeutic cancer vaccines (47, 165). Many academic and industrial 
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groups are developing workflows to generate personalized vaccines for cancer patients. Following 
exome sequencing and identification of mutations, an algorithm is used to predict potential peptides 
that can bind MHC class I molecules. These predicted immunogenic peptides are then used to 
produce a vaccine in the goal of generating protective tumor-specific CD8 T cell immunity (143). 
Mass spectrometry analysis of the HLA ligandome of tumor cells can be used to validate the in 
silico predictions and represents an additional way to identify tumor-associated immunogenic 
peptides. Compared to sequencing and prediction algorithms, this method has the advantage of 
identifying non-mutant self-peptides as relevant tumor antigens (166, 167). Although this 
therapeutic vaccine approach represents a great opportunity to treat cancer on a personalized level, 
some limitations need to be addressed including prohibitive costs due to specialized equipment and 
labor-intensive methods, but also the predictive algorithms need to be improved to take into 
consideration the high allelic diversity of MHC molecules between individuals. 
Both immunomodulation with checkpoint blockade and cancer vaccines ultimately aim at 
increasing the quantity and improving the function of tumor-specific T cells. Adoptive cell transfer 
represents another method to achieve this goal. As our study showed, adoptive transfer of naïve 
tumor-specific T cells can be efficient to eradicate late-stage cancer in mice when optimal signals 
are provided to these cells. However, the therapeutic rescue of tolerized CD8+ T cells was more 
difficult to achieve than preventing tolerization. This suggests that de novo priming may be more 
efficient to mount protective tumor-specific immunity than rescuing pre-existing immunity. From a 
translational perspective, this represents a major issue since cancer is mainly diagnosed at stages 
when tumor-specific immunity is already deviated and providing a large amount of fresh tumor-
specific cells remains challenging in a clinical setting. It is possible that lymphoablative 
conditioning of the host could improve responses to the combination of anti-CD40 + IL-2cx + IL-
12Fc or to other immunotherapies by eliminating negative interference from various cells while 
inducing in parallel a strong influx of naïve T cells. The efficacy of preconditioning 
lymphodepletion in cancer therapy has been demonstrated in mice and humans receiving adoptive 
cell therapy using cyclophosphamide and fludarabine combined with total-body irradiation (168, 
169).  
Another category of adoptive cell transfer emerged by combining the current knowledge of 
T cell activation and methods of genetic engineering. Chimeric antigen receptors (CARs) were 
created to enhance the effector function of transduced T cells (CAR-T) while being directed 
towards a specific tumor-associated antigen (170, 171). CARs can target surface molecules via a 
single-chain variable fragment (scFv) derived from an antibody fused to a hinge, a transmembrane 
domain and intracellular costimulatory domains such as CD28, 4-1BB, CD3ζ which provides 
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signals 1 and 2 (170). The efficacy of this approach is well established, although not yet approved 
as a therapy (172-175). However, it suffers from the lack of known targets specifically expressed on 
the cell surface of tumor cells. Nonetheless, adoptive transfer of genetically engineered tumor-
specific T cells has the potential to significantly improve clinical outcome for some cancers, but 
requires the identification of more tumor-specific targets. 
Therapies based on adoptive transfers are remarkably effective in humans (176-180). 
However, the major risk with adoptive transfer of T cells consists of on-target, but off-tumor 
effects. This on-target/off-tumor toxicity is caused by T cell responses against normal tissue 
expressing the target antigen. It can cause severe immune-mediated adverse reactions (irAEs) and 
represents a limitation for the use of such therapy (181-185). A safer approach was developed 
recently by transducing an inducible suicide gene as a safety switch to avoid irAEs. The inducible 
Caspase 9 (iCasp9) system allows for the rapid and selective elimination of more than 90% of 
transduced T cells in less than 30 minutes with a single dose of the non-toxic synthetic drug, 
AP1903 (186, 187). This molecule triggers the dimerization of iCasp9 resulting in rapid induction 
of apoptosis in cells expressing the transgene. The safety and efficacy of this system was 
demonstrated in children who received genetically modified T cells to enhance immune 
reconstitution in the context of haploidentical stem-cell transplants as treatment for relapsing acute 
leukemia. The bioinert dimerizing drug was given to patients in whom graft-versus-host-disease 
(GVHD) developed following transplantation and showed that a single dose was sufficient to end 
GVHD and prevent recurrence (187). 
Although the combination of adoptive T cell transfer with anti-CD40 + IL-2cx + IL-12Fc 
cured aggressive and poorly immunogenic late stage tumors in mice, its clinical translation remains 
difficult. Indeed, each compound of this combination can cause severe immune-related adverse 
events at high doses in humans (188, 189). This combination also causes side effects in mice that 
were not investigated thoroughly in our study, although we observed similar weight loss, 
splenomegaly and lymphocytosis than what was reported for anti-CD40 monotherapy (190, 191). 
The use of IL-2 complexes instead of recombinant IL-2 prevented pulmonary edema as described 
previously (192).  
Most side effects associated with therapies including cytokines or checkpoint blockade 
involve T cells (193-196), are dose-dependent and cover a broad range in onset from sudden to 
multiple weeks after initiation of therapy (188, 197). Of note, there are conflicting data about irAEs 
significantly correlating with the probability of response to immunotherapy and prolonged overall 
survival (197-201). Depending on the grade and the organ(s) affected by irAEs, the strategies vary 
to limit damages, but corticosteroids like prednisone are the most prevalent approach. In the case of 
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cytokine-release syndrome, blocking of IL-6 receptor with a monoclonal antibody like Tocilizumab 
has been used effectively in patients with leukemia undergoing immunotherapy (150). Although 
these approaches can counteract treatment-related adverse events, toxicity still limits the number of 
patients benefiting from immunotherapy. Thus, how to achieve maximal clinical efficacy while 
causing manageable toxicity remains a major challenge in the field. 
In conclusion, an optimal cancer immunotherapy should tackle multiple obstacles. 1) It 
should stimulate both the innate and adaptive arms of the immune system. 2) It should increase the 
frequency of fresh tumor-specific T cells and adoptive transfer or cancer vaccines may represent 
optimal ways of achieving this goal. 3) Therapeutic administration of compounds increasing the 
quality of costimulation is desirable. 4) Survival and differentiation of tumor-infiltrating T cells 
should be supported by local cytokine therapy. 5) Innovative delivery systems, careful dosage and 
safety switches may represent key enabling factors to limit immune-related adverse events and 
achieve maximal efficacy. 
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Spontaneous Peripheral T-cell Responses toward the
Tumor-Associated Antigen Cyclin D1 in Patients with Clear
Cell Renal Cell Carcinoma
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Stefan Stevanovic4, Peter Schraml3, Holger Moch3, Alexander Knuth1, and Maries van den Broek1
Abstract
Renal cell carcinoma (RCC) is a heterogeneous groupof kidney cancerswith clear cell RCC (ccRCC) as themajor
subgroup. To expand the number of clinically relevant tumor-associated antigens (TAA) that can be targeted by
immunotherapy, we analyzed samples from 23 patients with primary ccRCC for the expression and immuno-
genicity of various TAAs. We found high-frequency expression of MAGE-A9 and NY-ESO-1 in 36% and 55% of
samples, respectively, and overexpression of PRAME, RAGE-1, CA-IX, Cyclin D1, ADFP, C-MET, and RGS-5 in many
of the tumor samples. We analyzed the blood of patients with HLA-A2þ ccRCC for the presence of CD8þ T cells
speciﬁc for TAA-derived HLA-A2–restricted peptides and found spontaneous responses to cyclin D1 in 5 of 6
patients with Cyclin D1–positive tumors. Cyclin D1–speciﬁc CD8þ T cells secreted TNF-a, IFN-g , and interleukin-
2 (IL-2), and degranulated, indicating the presence of polyfunctional tumor-speciﬁc CD8þ T cells in the blood of
these patients with ccRCC. The high frequency (43%) of Cyclin D1 overexpression and the presence of functional
cyclin D1–speciﬁc T cells in 83% of these patients with ccRCC suggest that cyclin D1 may be a target for
immunotherapeutic strategies. Cancer Immunol Res; 1(5); 288–95. 2013 AACR.
Introduction
The immune system recognizes and controls tumors
through a process called cancer immune surveillance (1).
Studies showed a correlation between tumor inﬁltration by
T cells and patient survival in various cancers (2). Furthermore,
spontaneous immunity against tumor-associated antigens
(TAA) canbe detected in patientswith cancer (3). TAAs include
cancer-testis (CT) antigens, differentiation antigens, mutated
proteins, overexpressed proteins, and viral antigens (4). Boost-
ing spontaneous TAA-speciﬁc immunity is a low-toxicity strat-
egy that resulted in objective clinical responses in some
patients with cancer (5).
Renal cell carcinoma (RCC) is a heterogeneous cancer that
encompasses about 90% of all human kidney tumors, and clear
cell RCC (ccRCC) is the major histologic subgroup (6). About
one third of RCC has already metastasized at the time of
diagnosis, and 20% to 50% of resected patients develop meta-
stasis (7). Treatment of advanced and metastatic RCC is
challenging due to its relative resistance to chemo- and radio-
therapy (8).
Evidence supporting RCC as an immunogenic cancer
includes cases of spontaneous regressions, increased incidence
in immunosuppressed patients, and the high density of tumor-
inﬁltrating leukocytes (TIL; ref. 9). Since the 1980s, immuno-
stimulatory compounds such as interleukin-2 (IL-2) and IFN-a
are being used to treat RCC. Despite modest therapeutic
efﬁcacy in some patients, the concomitant severe systemic
toxicity remains a problem (8). Furthermore, data showing
TAA-speciﬁc immunity in patients with RCC are scarce.
We conducted quantitative reverse transcription PCR (qRT-
PCR) on samples from 23 patients with primary ccRCC for the
expression of genes encoding cancer-testis antigens MAGE-A1
(CT1.1), -A3 (CT1.3), -A4 (CT1.4), -A9 (CT1.9), -A10 (CT1.10),
synovial sarcoma X breakpoint 2 (SSX2/CT5.2), New York
esophageal I (NY-ESO-1/CT6.1), L antigen 1 (LAGE-1/CT6.2)
and MAGE-C1 (CT7), carbonic anhydrase IX (CA-IX/G250),
renal antigen 1 (RAGE-1), preferentially expressed antigen of
melanoma (PRAME), adipose differentiation-related protein
(adipophilin/ADFP), C-MET proto-oncogene, cyclin D1
(CCND1), and regulator of G-protein signaling 5 (RGS-5). We
also determined whether spontaneous T-cell responses were
elicited against any of these antigens.
Materials and Methods
Patients
Patients with ccRCC underwent full or partial nephrectomy
as part of their standard treatment at the Department of
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Urology, University Hospital Zurich (Zurich, Switzerland),
between 2008 and 2011. Tumor specimens and peripheral
whole blood were obtained following informed consent in
accordance with the Declaration of Helsinki. The local ethics
committee approved the study (EK-1017 and EK-1634).
Detailed patients' characteristics are listed in Table 1. All
patients were HLA-A2–typed using ﬂuorescein isothiocyanate
(FITC)–conjugated HLA-A2–speciﬁc or isotype control anti-
bodies (BioLegend), on a CyAn ADP 9 ﬂow cytometer (Beck-
man Coulter), and data were analyzed using FlowJo software
(TreeStar).
Processing of blood and tumor samples
Peripheral blood mononuclear cells (PBMC) were isolated
fromperipheral blood by Ficoll (Ficoll-Paque PLUS; GEHealth-
care) density centrifugation. Immediately after surgery, a small
piece of tumor tissue was snap-frozen in liquid nitrogen for
RNA isolation. The remaining tumor was digested with 6 U/mL
DNase I type IV (Sigma), 1 mg/mL collagenase IV (Sigma) in
Dulbecco's modiﬁed Eagle medium (DMEM; Gibco), 50 U/mL
penicillin, and 50U/mL streptomycin (Gibco) for 1 to 2 hours at
37C. The resulting single-cell suspensions and the PBMCs
were cryopreserved at 80C until analysis.
RNA isolation
Total RNA was extracted from snap-frozen ccRCC tumor
samples using the RNeasy Mini Kit (Qiagen) followed by
digestion with DNase I (New England BioLabs) according to
the manufacturer's instructions.
Quantitative real-time PCR
The concentration and purity of RNA were evaluated using
the NanoDrop ND-1000 spectrophotometer (NanoDrop Tech-
nologies). Using the High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems), 500 ng of RNA was reverse
transcribed according to the manufacturer's instructions;
cDNA was stored at 20C until qRT-PCR analysis was con-
ducted on a Rotor-Gene Q real-time PCR cycler (Qiagen) using
the commercially available TaqMan reagents with optimized
primer and probe concentrations (TaqMan gene expression
assays; Applied Biosystems; Table 2). After an initial hold for 2
minutes at 50Cand 10minutes at 95C, the probeswere cycled
45 times at 95C for 15 seconds and at 60C for 60 seconds. All
PCR reactions were carried out in triplicates. Threshold cycle
(Ct) values were determined with the Rotor-Gene Q Series
software 1.7. DCt values were calculated by normalizing the
Table 1. Patient information
Histology ccRCC
Patient number n ¼ 23
Age, y 37–84 (64.1  11)
Pathologic stage pT1 1
pT1a 8
pT1b 4
pT2 3
pT3 0
pT3a 3
pT3b 4
pT3c 0
pT4 0
Table 2. TaqMan assays of TAAs and derived HLA-A2–restricted peptides
TaqMan assay ID Position Peptide sequence Peptide source
MAGE-A1 Hs00607097_m1 278–286 KVLEYVIKV Not used
MAGE-A3 Hs00366532_m1 271–279 FLWGPRALVd Not used
MAGE-A4 Hs00365979_m1 230–239 GVYDGREHTV Not used
MAGE-A9 Hs00893224_m1 223–231 ALSVMGVYV Thermo Scientiﬁc
MAGE-A10 Hs01560792_m1 254–262 GLYDGMEHL Not used
SSX2 Hs00817683_m1 41–49 KASEKIFYV Not used
NY-ESO-1 Hs00265824_m1 157–165 SLLMWITQC Bio Synthesis
LAGE-1 Hs00535628_m1 41214 MLMAQEALAFL Not used
157–165 SLLMWITQV Not used
MAGE-C1 Hs00193821_m1 959–968 ILFGISLREV Not used
1083–1091 KVVEFLAML Not used
PRAME Hs00196132_m1 425–433 SLLQHLIGL Thermo Scientiﬁc
100–108 VLDGLDVLL Thermo Scientiﬁc
RAGE-1 Hs00179504_m1 32–40 PLPPARNGGL Thermo Scientiﬁc
352–360 LKLSGVVRL Thermo Scientiﬁc
CA-IX Hs00154208_m1 254–262 HLSTAFARV Thermo Scientiﬁc
CCND1 Hs00765553_m1 101–109 LLGATCMFV S. Stevanovic, Tuebingen
228–236 RLTRFLSRV S. Stevanovic, Tuebingen
ADFP Hs00765634_m1 129–137 SVASTITGV S. Stevanovic, Tuebingen
C-MET Hs00179845_m1 654–662 YVDPVITSI S. Stevanovic, Tuebingen
RGS-5 Hs00186212_m1 5–13 LAALPHSCL S. Stevanovic, Tuebingen
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target mRNA levels to the endogenous control 18s-rRNA
(Hs03928990_g1; Applied Biosystems). Testis cDNA generated
from human testes total RNA (Invitrogen) served as positive
control for expression analysis of cancer-testis antigens. As
qRT-PCR forMAGE-A9 suggested low expression in the healthy
kidney control (CT 35,DCT30), expression in ccRCC specimens
was considered positive at a CT < 35 and a DCt < 30. For
overexpressed antigens, DCt levels of tumors were compared
with DCt levels of healthy kidney control (human kidney total
RNA; Invitrogen) using the 2DDCt formula. Only changes 2-fold
or more were considered as overexpression.
Genomic DNA extraction
Punch biopsies from parafﬁn-embedded ccRCC samples
were incubated (10 minutes at 95C) with 300 mL of buffer
containing 20 mmol/L Tris pH 8.0, 20 mmol/L EDTA and 1%
SDS. After cooling down, 3 mL of Proteinase K (18  4 mg/mL;
Roche) was added to each sample and incubated at 55C for
72 hours. Digested samples were centrifuged and 4 volumes
of RLT buffer (AllPrepDNA/RNAMini Kit; Qiagen), were added
to the supernatant. Genomic DNA was extracted following
the manufacturer's protocol.
Cyclin D1 sequencing
Puriﬁed genomic DNA was ampliﬁed using the Phusion Hot
Start High-Fidelity DNA Polymerase (Finnzymes) with the
following PCR conditions: 10 minutes at 98C, followed by
34 cycles of 30 seconds at 98C, 30 seconds at 68C, 20 seconds
at 72Cwith a ﬁnal elongation of 5 minutes at 72C. Sequences
encoding the HLA-A2–restricted CTL epitope corresponding
to cyclin D1 amino acids 101–109 or 228–236 were ampliﬁed
by using the forward primer 50-TGCGAGGAACAGAAGTGC-
GA-30/reverse primer 50-TCCAGTGGTTACCAGCAGCTC-30 or
forward primer 50-TGCTCACAGCCTCCTTCCCT-30/reverse
primer 50-TCGGCATTTCCGTGGCACTA-30 respectively. PCR
products were puriﬁed using the QIAquick Gel Extraction Kit
(Qiagen) and sequenced using the same ampliﬁcation primers.
MACS sorting and in vitro stimulation
T-cell stimulation was conducted as described previously
(10). Brieﬂy, CD8þ and CD4þ T cells were isolated sequen-
tially from PBMCs by positive selection using MACS (Milte-
nyi Biotech) according to the manufacturer's instructions.
The remaining CD8CD4 fraction was used as antigen-
presenting cells (APC), which were loaded with 105 mol/L
of each peptide (Table 2). For in vitro stimulation, 5  105
CD8þ T cells were incubated with 5  105 loaded and
irradiated (30 Gy) APCs in 96-well ﬂat-bottomed plates.
Cells were cultured for 9 days in 200 mL of TC-RPMI [i.e.,
RPMI (Gibco), supplemented with NaHCO3 (2 g/L; Sigma),
L-glutamine (2 mmol/L, Sigma), penicillin and streptomycin
(50 U/mL; Gibco), minimum essential medium nonessential
amino acids (1; Gibco), sodiumpyruvate (1 mmol/L;
Gibco), 104 mol/L b-mercaptoethanol (Sigma), and 10%
pooled human serum plus DNase I (6 U/mL; Sigma)]. T-APCs
were generated from puriﬁed autologous CD4þ T cells
stimulated with 1 mg/mL phytohemagglutinin (PHA; Sigma)
and 100 U/mL recombinant IL-2 (R&D Systems) during the
9-day culture. T-APCs were used as APCs during the short
in vitro stimulation before intracellular cytokine staining
(ICS). Medium was exchanged every second day with TC-
RPMI containing 25 U/mL of IL-2.
Intracellular cytokine staining
At day 9, the presence of TAA-speciﬁc T cells was tested by
short-term restimulation with relevant peptides, followed by
ICS. Brieﬂy, T cells were stimulated with peptide-loaded autol-
ogous T-APCs at a 1:2 ratio for 5 hours in the presence of
brefeldin A (10 mg/mL; Sigma), monensin (10 mg/mL; Sigma),
1 mg/mL anti-CD28/49d (BD), and appropriately diluted phy-
coerythrin (PE)-labeled anti-CD107a antibody. Before addition
to the assay, T-APCs were labeled with 2 mmol/L carboxy-
ﬂuoresceinsuccinimidyl ester (CFSE; Sigma), which allowed
their exclusion before analysis. Surface staining for CD45-
PerCP, CD3-Paciﬁc Orange (Invitrogen), CD8-ECD (Beckman
Coulter), CD14-FITC, CD16-FITC, CD19-FITC, and live-dead
staining (LIVE/DEAD Fixable Green Dead Cell Stain Kit; Invi-
trogen) was conducted in PBS [NaCl (136 mmol/L; Fluka), Na2
HPO4 (8 mmol/L; Roth), KH2PO4 (1.5 mmol/L; Roth), pH 7] for
20 minutes at room temperature. Subsequently, cells were
ﬁxed with 4% formalin (Kantonsapotheke Zurich) and incu-
bated for 5 minutes at room temperature with permeabiliza-
tion buffer [PBS supplemented with 2 mmol/L EDTA (Sigma),
2% fetal calf serum (FCS; PAA Laboratories), 0.05% NaN3
(Sigma), and 0.1% Saponin (Sigma)]. Intracellular staining was
conducted using IFN-g-APC, TNF-a-PECy7 (ebiosciences), and
IL-2-Paciﬁc Blue antibodies in permeabilization buffer for 20
minutes at room temperature in the dark. Cells were washed
once with permeabilization buffer and resuspended in PBS
containing 1% formalin. Samples were evaluated by ﬂow
cytometry and data were analyzed with FlowJo software as
described earlier. Unless stated differently, all antibodies were
purchased from BioLegend.
Tetramer staining
PBMCs or digested tumor samples were stained with
tetramers for the presence of TAA-speciﬁc CD8þ T cells.
Brieﬂy, cells were resuspended in PBS and incubated for 10
minutes at 37C with PE-labeled tetramers consisting of
HLA-A2 plus cyclin D1101–109, cyclin D1228–236, CMV495–503 or
FLU-MATRIX58–66, followed by incubation with anti-CD45
APC, anti-CD8 Paciﬁc Blue (both BioLegend), and live-dead
stain (LIVE/DEAD Fixable Aqua Dead Cell Stain Kit; Invi-
trogen) for 15 minutes at 4C. Cells were washed once with
PBS and resuspended in PBS containing 1% formalin. Sam-
ples were evaluated by ﬂow cytometry and data were ana-
lyzed with FlowJo software. The percentage of tetramer-
positive cells was determined after gating on live, CD45þ
CD8þ cells.
Western blotting
The presence of cyclin D1–speciﬁc immunoglobulin G (IgG)
in patient sera was tested by Western blotting as described
previously (11) using recombinant human cyclin D1 (Abnova
cat. no. H00000595-PO1). Sera from 22 patients with ccRCC
were used at a 1:250 dilution. MaxPab mouse polyclonal anti-
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human CCND1 (Abnova cat. no. H00000595-BO1P) was used
as positive control at 1:1,000 dilution. Horseradish peroxidase
(HRP)–conjugated goat anti-mouse IgG (Jackson Immuno-
Research; 115-035-008) was used as positive control and
HRP-conjugated goat anti-human IgG (Jackson Immuno-
Research 109-035-006) for serum samples at a dilution of
1:25,000. Blots were developed with Western Lightning Plus
enhanced chemiluminescence (ECL) reagents (PerkinElmer
cat. no. NEL104001EA) and signals were measured using a
Fusion FX7 machine (VILBER LOURMAT).
Results
Frequent expression of TAAs in primary ccRCC tumor
samples
The expression of nine cancer-testis and seven other anti-
gens in 23 primary ccRCC specimens was analyzed by qRT-
PCR. We found expression of MAGE-A9 and NY-ESO-1 in 36%
and 55%of samples, respectively, and did not ﬁnd expression of
the other seven cancer-testis antigens in any samples (Fig. 1A).
Although MAGE-A9 and NY-ESO-1 were frequently expressed,
their expression levels were very low (Fig. 1B). Overexpression
of RAGE-1 in 13%, C-MET in 30%, PRAME in 39%, Cyclin D1 in
43%, ADFP in 65%, RGS-5 in 83%, and CA-IX in 96% of ccRCCs
specimens was also observed (Fig. 1A and B). More than 50% of
the ccRCC specimens coexpressed four to six different TAAs
(Fig. 1C). We found no evidence for preferred coexpression of
particular TAAs (Fig. 1D).
Spontaneous cyclin D1–speciﬁc CD8þT-cell responses in
patients with primary ccRCC
Because of limited specimen availability, we selected HLA-
A2þ patients and used previously described HLA-A2–restrict-
ed peptides for stimulation of PBMCs (http://www.cancerim-
munity.org/CTdatabase; refs. 12–14; summarized in Table 2).
Figure 1. Expression of TAA transcripts in ccRCC specimens. RNA was isolated from 23 primary ccRCC samples and reverse transcribed, and cDNA was
used as a template for qRT-PCR analysis. A, frequency of expressed TAAs in primary ccRCC samples. B, detectedDCT levels for the different TAA transcripts
of the individual tumor samples after normalization to the endogenous control (18SrRNA). Results from tumor samples are represented as open, from testis as
ﬁlled, and from healthy kidney as half-ﬁlled symbols. C and D, coexpression of TAAs in primary ccRCC samples.
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After in vitro culture for 9 days with the relevant peptides, we
conducted a 5-hour restimulation with the same peptides in
the presence of brefeldin A and monensin, followed by ICS for
effector cytokines TNF-a, IFN-g , and IL-2, and staining for
degranulation (surface CD107a). We found CD8þ T cells spe-
ciﬁc for cyclin D1–derived peptides in 5 of 6 HLA-A2þ patients,
whose tumors overexpressed Cyclin D1 (Fig. 2A), but not for
any of the other peptides tested (data not shown). Because of
limitedmaterial, the readout for patient samples Z-H-903, Z-H-
209, Z-H-929, and Z-H-1055 was conducted with both cyclin
D1–derived peptides (cyclin D1101–109 and cyclin D1228–236)
together. Because there were enough specimens from patients
Z-H-1184 and Z-H-1257, we analyzed the two cyclin D1–
derived epitopes separately and found that responses in both
patients were directed against cyclin D1101–109 as illustrated by
representative staining of specimens from patient Z-H-1184
(Fig. 2B). Furthermore, the cyclin D1–speciﬁc CD8þ T cells in
all 5 patients were polyfunctional although only a few cells
secreted IL-2 (Fig. 2C). To exclude the possibility that the cyclin
D1–speciﬁc CD8þT-cell responses were due to in vitro priming
rather than in vivo induction by Cyclin D1–overexpressing
tumors, we carried out a similar experiment with PBMCs from
3 healthy, HLA-A2þ donors. CMV495–503 was used as positive
control because these donors were selected by the presence of
CMV tetramer-speciﬁc CD8þ T cells. We did not ﬁnd cyclin
D1–speciﬁc CD8þ T-cell responses in these healthy donors,
whereas CMV-speciﬁc CD8þ responseswere readily detectable
by ICS (data not shown).
To conﬁrm the presence of cyclin D1–speciﬁc T cells, we
carried out ex vivo tetramer staining on PBMCs (Supple-
mentary Fig. S1A) and TILs (Supplementary Fig. S1B) from
patients with ccRCC when sufﬁcient material was available.
In PBMCs from patient Z-H-209, who did not show a cyclin
D1–speciﬁc response after in vitro stimulation, we also did
not detect cyclin D1 tetramer-positive T cells. However, in
PBMCs from patients Z-H-903, Z-H-1055, and Z-H-1184, who
responded to in vitro cyclin D1–speciﬁc peptide stimulation,
we detected cyclin D1–speciﬁc T cells by tetramer staining
(Supplementary Fig. S1A). Although we did not ﬁnd cyclin
D1 tetramer-speciﬁc T cells in TILs of patient Z-H-929,
whose PBMCs responded weakly to cyclin D1–speciﬁc pep-
tide stimulation in vitro, we detected cyclin D-1 tetramer-
speciﬁc T cells in TILs of patients Z-H-1184 and Z-H-1257,
whose PBMCs secreted cytokines upon peptide stimulation
in vitro (Supplementary Fig. S1B).
To investigate whether cyclin D1 induced humoral
immune response in patients with ccRCC, particularly those
who overexpress Cyclin D1, we tested for cyclin D1–speciﬁc
antibodies by Western blotting but did not ﬁnd cyclin D1–
speciﬁc antibodies in the sera of the 22 patients tested
(Supplementary Fig. S2).
Discussion
To expand the number of clinically relevant TAAs that can
be targeted by immunotherapy in patients with RCC, we
investigated the expression of nine cancer-testis antigens and
seven other antigens (15) in samples from 23 patients diag-
nosed with primary ccRCC. Most tumors expressed more than
one TAA, which has been described for other tumor entities
(16–18), and which enables therapeutic-targeting of multiple
antigens at the same time.
Except for MAGE-A9 and NY-ESO-1, we did not detect
expression of the other seven cancer-testis antigens in our
patient cohort. Although two studies showed expression for
MAGE-A3 and -A4 in RCC (19, 20), our results are in line with
those described in a previous review on cancer-testis antigens
(21). The expression frequency ofMAGE-A9 in RCC is similar to
that shown by Oehlrich and colleagues (12); however, we found
only very low levels of MAGE-A9 transcripts. As Oehlrich and
colleagues have reported (12), we also detected a signal for
MAGE-A9 in the healthy kidney tissue control. The frequency of
NY-ESO-1 expression in CCR was unexpected on the basis of
immunohistochemistry data published over a decade ago (22–
24). The discrepancy may be explained by the highly sensitive
qRT-PCR method we used that allowed the detection of very
low levels of NY-ESO-1 transcripts. Although RAGE-1 was the
ﬁrst antigen recognized by autologous T cells from a human
RCC cell line, it was only detected in 1 of 57 RCC samples (25).
Our results (13%) are in agreement with studies that identiﬁed
higher expression frequencies, which presumably is also due to
the more sensitive methods used (12, 22). The frequency of
PRAME-expression (39%) in ccRCC is in accordance with
previously published reports (20, 22).
The von Hippel-Lindau (VHL) protein is mutated in most
ccRCC samples, leading to reduced proteolytic degradation of
hypoxia-inducible factor-a (HIF-a), resulting in upregulated
HIF-a–mediated transcriptional programs (26). CA-IX is an
HIF-a target gene that is frequently expressed in RCC but very
rarely detected in normal kidney tissue (27). We observed an
overexpression ofCA-IX in all but one ccRCC samples. CA-IX has
been identiﬁed as a therapeutic target for RCC (13, 28, 29), and
evaluated in clinical studies (30–32), but it has not yet induced
strong antitumor immune responses. In addition to CA-IX,
ADFP, Cyclin D1, C-MET, and RGS-5 are also overexpressed in
ccRCC (14). In contrast to published reports (33, 34), we found
that ADFP expressed more frequently (65%) than C-MET (30%).
Cyclin D1 is a cell-cycle regulator crucial for the G1–S transition
(35) and is overexpressed in many cancers including colorectal
and breast carcinoma (36, 37). We found that cyclin D1 was
overexpressed in 43% of the primary ccRCC samples, a ﬁnding
that was similar to the previous published data (38–40).
Many factors affect the success of immunotherapy (22).
Despite the high frequency of expression (55%) of NY-ESO-1
Figure 2. Cyclin D1–speciﬁc CD8þ T-cell response in PBMCs of patients with ccRCC. CD8þ T cells from PBMCs of HLA-A2þ patients with cyclin
D1–overexpressing tumors were stimulated for 9 days with cyclin D1–derived peptides in the presence of IL-2. Restimulation was carried out using both
cyclin D1–derived epitopes (cyclin D1101–109 and cyclin D1228–236) together, separately, or no peptide as highlighted in the ﬁgure, followed by
surface staining for CD107a and intracellular staining for TNF-a, IFN-g , and IL-2. Cytokine production of CD8þ T cells was measured after gating on
live CD45þ, CD3þ, CD8þ, CD14, CD16, and CD19 cells. A, summary of results from 6 individual patients. B, representative staining (patient
Z-H-1184) of single cytokine secretion and (C) polyfunctional cytokine response.
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in ccRCC samples, which is one of the most immunogenic
cancer-testis antigens (24, 41), we did not ﬁnd NY-ESO-1–
speciﬁc CD8þT-cell responses in any of the patients with HLA-
A2þ ccRCC, whichmay be explained by the low level ofNY-ESO-
1 expression. ADFP, C-MET, and RSG-5 are not immunogenic
in patients with ccRCC, as we did not detect T-cell responses
speciﬁc for these antigens, despite their frequent overexpres-
sion. This ﬁnding is in agreement with previously published
data on rare T-cell responses in patients with ccRCC (15), even
though ADFP- and C-MET–speciﬁc T cells could be expanded
from the blood of healthy donors (33, 34).RGS-5 overexpression
did not result in detectable RGS-5–speciﬁc T-cell responses
in our cohort, although such responses were reported in the
blood of healthy donors and patients with acute myeloid
leukemia (42). In contrast, we detected cyclin D1–speciﬁc
CD8þ T cells in the blood of 5 of 6 patients with HLA-A2þ
ccRCC, whose tumors overexpressed Cyclin D1. Unlike cyclin-
dependent kinase 4 (CDK4) in melanoma (43), we did not
ﬁnd a mutation in the two Cyclin D1 epitopes in ccRCC (data
not shown).
Ex vivo tetramer staining conﬁrmed the presence of
cyclin D1–speciﬁc T cells in patients whose CD8þ PBMCs
secreted cytokines upon in vitro cyclin D1–speciﬁc peptide
stimulation. Although we detected a higher frequency of
T cells speciﬁc for cyclin D1228–236 by tetramer in blood and
TILs, we found a higher frequency of T cells speciﬁc for
Cycllin D1101–109 after in vitro restimulation. Because cyclin
D1228–236 is the immunodominant peptide, it may induce
more extensive in vivo proliferation of speciﬁc T cells and
thus compromise their ability to further expand in vitro.
Alternatively, tetramer-positive T cells may not be function-
al, suggesting a preferential functional exhaustion of T cells
speciﬁc for cyclin D1228–236.
There is no association identiﬁed between Cyclin D1 ex-
pression and ccRCC prognosis (40), although Cyclin D1 over-
expression is associated with shorter patient survival in other
cancers and thus represents an interesting therapeutic target
(44). However, cyclin D1 is difﬁcult to target as it is expressed
in the cytosol and lacks intrinsic enzymatic activity. One
approach is to block its activity indirectly by inhibiting asso-
ciated kinases with kinase inhibitors (45); however, this strat-
egy does not interfere with its kinase-independent tumor-
promoting effects.
Cyclin D1 induces T-cell responses in mantle cell lymphoma
and colon cancer, and antibodies in prostate cancer (46–49),
andwas identiﬁed as a target for immunotherapy inmantel cell
lymphoma (50).
To our knowledge this is the ﬁrst study that describes
naturally occurring cyclin D1–speciﬁc CD8þ T-cell responses
in patients with cancer. Importantly, these responses have poly-
functional effector characteristics. We therefore propose cyclin
D1 as a target for immunotherapy in patients with ccRCC.
Disclosure of Potential Conﬂicts of Interest
No potential conﬂicts of interest were disclosed.
Authors' Contributions
Conception and design: S.R. Dannenmann, T. Hermanns, A. Knuth, M. van den
Broek
Development of methodology: S.R. Dannenmann, A. Bransi, H. Moch, A.
Knuth, M. van den Broek
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): S.R. Dannenmann, T. Hermanns, A. Bransi, C. Matter,
L. von Boehmer, H. Moch, A. Knuth
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): S.R. Dannenmann, A. Bransi, A. Knuth, M. van den
Broek
Writing, review, and/or revision of the manuscript: S.R. Dannenmann,
A. Bransi, S. Stevanovic, P. Schraml, H. Moch, A. Knuth, M. van den Broek
Administrative, technical, or material support (i.e., reporting or orga-
nizing data, constructing databases): T. Hermanns, A. Bransi, C. Matter,
L. von Boehmer, S. Stevanovic, P. Schraml, H. Moch, A. Knuth, M. van den Broek
Study supervision: H. Moch, A. Knuth, M. van den Broek
Acknowledgments
The authors thank Maurizio Provenzano and Giovanni Sais (Department of
Urology, University Hospital Zurich) for advice in planning the qRT-PCR
experiment.
Grant Support
This work was supported in part by the Cancer Research Institute/Cancer
Vaccine Collaborative (to A. Knuth), the Hanne Liebermann Foundation (to A.
Knuth), the Dr. Leopold and Carmen Ellinger Foundation Zurich (to A. Knuth
andM. vandenBroek), the Science FoundationOncology (SFO; toA. Knuth and S.
R. Dannenmann), the Swiss National Science Foundation (31003A-122147, to M.
van den Broek and A. Bransi; 3238BO-103145, to H. Moch), the HartmannM€uller
Foundation Zurich (to S.R. Dannenmann), the Alumni Grant University
Zurich (to L. von Boehmer), and the Deutsche Forschungsgemeinschaft (SFB
685; to S. Stevanovic).
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this
fact.
Received August 5, 2013; accepted August 13, 2013; published OnlineFirst
September 25, 2013.
References
1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating
immunity's roles in cancer suppression and promotion. Science
2011;331:1565–70.
2. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune
contexture in human tumours: impact on clinical outcome. Nat Rev
Cancer 2012;12:298–306.
3. Vesely MD, KershawMH, Schreiber RD, SmythMJ. Natural innate and
adaptive immunity to cancer. Annu Rev Immunol 2011;29:235–71.
4. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immuno-
surveillance and immunotherapy. Nat Immunol 2001;2:293–9.
5. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of
age. Nature 2011;480:480–9.
6. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ.
Prognostic utility of the recently recommended histologic classiﬁca-
tion and revised TNM staging system of renal cell carcinoma: a Swiss
experience with 588 tumors. Cancer 2000;89:604–14.
7. Vickers MM, Heng DY. Prognostic and predictive biomarkers in renal
cell carcinoma. Target Oncol 2010;5:85–94.
8. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell
carcinoma. J Clin Oncol 2006;24:5601–8.
9. Itsumi M, Tatsugami K. Immunotherapy for renal cell carcinoma. Clin
Dev Immunol 2010;2010:284581.
10. Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von
Boehmer L, et al. Fine analysis of spontaneous MAGE-C1/CT7-spe-
ciﬁc immunity in melanoma patients. Proc Natl Acad Sci U S A
2010;107:15187–92.
11. Curioni-Fontecedro A, Knights AJ, Tinguely M, Nuber N, Schneider C,
Thomson CW, et al. MAGE-C1/CT7 is the dominant cancer-testis
Dannenmann et al.
Cancer Immunol Res; 1(5) November 2013 Cancer Immunology Research294
on January 28, 2015. © 2013 American Association for Cancer Research. cancerimmunolres.aacrjournals.orgDownloaded from 
Published OnlineFirst September 25, 2013; DOI: 10.1158/2326-6066.CIR-13-0113 
94
antigen targeted by humoral immune responses in patients with
multiple myeloma. Leukemia 2008;22:1646–8.
12. Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S,
Stevanovic S, et al. Generation of RAGE-1 and MAGE-9 peptide-
speciﬁc cytotoxic T-lymphocyte lines for transfer in patients with renal
cell carcinoma. Int J Cancer 2005;117:256–64.
13. Vissers JL, De Vries IJ, SchreursMW, Engelen LP,Oosterwijk E, Figdor
CG, et al. The renal cell carcinoma-associated antigenG250encodes a
human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by
cytotoxic T lymphocytes. Cancer Res 1999;59:5554–9.
14. Kruger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J, et al.
Lessons to be learned from primary renal cell carcinomas: novel tumor
antigens and HLA ligands for immunotherapy. Cancer Immunol
Immunother 2005;54:826–36.
15. Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee HG. Immuno-
therapy of renal cell carcinoma. Cancer Immunol Immunother 2007;56:
117–28.
16. Walter A, BaryschMJ, Behnke S, Dziunycz P, Schmid B, Ritter E, et al.
Cancer-testis antigens and immunosurveillance in human cutaneous
squamous cell and basal cell carcinomas. Clin Cancer Res 2010;16:
3562–70.
17. Bolli M, Schultz-Thater E, Zajac P, Guller U, Feder C, Sanguedolce F,
et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis
antigens: a tissue microarray study. Int J Cancer 2005;115:960–6.
18. von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Her-
manns T, et al. MAGE-C2/CT10 protein expression is an independent
predictor of recurrence in prostate cancer. PLoS ONE 2011;6:e21366.
19. Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S.
Expression ofMAGEgenes in renal cell carcinoma. Int JMolMed1998;
2:57–60.
20. Ringhoffer M, Muller CR, Schenk A, Kirsche H, Schmitt M, Greiner J,
et al. Simultaneous expression of T-cell activating antigens in renal cell
carcinoma: implications for speciﬁc immunotherapy. J Urol 2004;171:
2456–60.
21. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review,
standardization, and commentary. Cancer Immun 2004;4:1.
22. Neumann E, Engelsberg A, Decker J, Storkel S, Jaeger E, Huber C,
et al. Heterogeneous expression of the tumor-associated antigens
RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma:
candidates for T-cell-based immunotherapies? Cancer Res 1998;58:
4090–5.
23. Jungbluth AA, Chen YT, Stockert E, BusamKJ, Kolb D, Iversen K, et al.
Immunohistochemical analysis of NY-ESO-1 antigen expression in
normal and malignant human tissues. Int J Cancer 2001;92:856–60.
24. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, et al. A
testicular antigen aberrantly expressed in human cancers detected by
autologous antibody screening. Proc Natl Acad Sci U S A 1997;94:
1914–8.
25. Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek
CW, Patard JJ, et al. A new gene coding for an antigen recognized by
autologous cytolytic T lymphocytes on a human renal carcinoma.
Immunogenetics 1996;44:323–30.
26. Frew IJ, Krek W. pVHL: a multipurpose adaptor protein. Sci Signal
2008;1:pe30.
27. Murakami Y, KandaK, TsujiM, KanayamaH,KagawaS.MN/CA9 gene
expression as a potential biomarker in renal cell carcinoma. BJU Int
1999;83:743–7.
28. Vissers JL, De Vries IJ, Engelen LP, Scharenborg NM, Molkenboer J,
Figdor CG, et al. Renal cell carcinoma-associated antigen G250
encodes a naturally processed epitope presented by human leukocyte
antigen-DR molecules to CD4(þ) T lymphocytes. Int J Cancer
2002;100:441–4.
29. Oosterwijk E, Debruyne FM, Schalken JA. The use of monoclonal
antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol
1995;22:34–41.
30. Bleumer I, TiemessenDM,Oosterwijk-Wakka JC, VollerMC, DeWeijer
K, Mulders PF, et al. Preliminary analysis of patients with progressive
renal cell carcinoma vaccinated with CA9-peptide-pulsed mature
dendritic cells. J Immunother 2007;30:116–22.
31. Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E,
Wuest T, et al. Targeted therapy of renal cell carcinoma: syner-
gistic activity of cG250-TNF and IFNg. Int J Cancer 2009;125:
115–23.
32. Hernandez JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen
D, et al. Novel kidney cancer immunotherapy based on the granulo-
cyte-macrophage colony-stimulating factor and carbonic anhydrase
IX fusion gene. Clin Cancer Res 2003;9:1906–16.
33. Schmidt SM, Schag K, Muller MR, Weinschenk T, Appel S, Schoor O,
et al. Induction of adipophilin-speciﬁc cytotoxic T lymphocytes using a
novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer
Res 2004;64:1164–70.
34. Schag K, Schmidt SM, Muller MR, Weinschenk T, Appel S, Weck MM,
et al. Identiﬁcation of C-met oncogene as a broadly expressed tumor-
associated antigen recognized by cytotoxic T-lymphocytes. Clin Can-
cer Res 2004;10:3658–66.
35. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell
1995;81:323–30.
36. Bartkova J, Lukas J, Strauss M, Bartek J. The PRAD-1/cyclin D1
oncogene product accumulates aberrantly in a subset of colorectal
carcinomas. Int J Cancer 1994;58:568–73.
37. Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ. Immuno-
histochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol
1994;102:695–8.
38. Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G. Cyclin-D1
expression in human renal-cell carcinoma. Int J Cancer 1999;84:268–
72.
39. Lin BT, Brynes RK, Gelb AB, McCourty A, Amin MB, Medeiros LJ.
Cyclin D1 expression in renal carcinomas and oncocytomas: an
immunohistochemical study. Mod Pathol 1998;11:1075–81.
40. Dahinden C, Ingold B, Wild P, Boysen G, Luu VD, Montani M, et al.
Mining tissue microarray data to uncover combinations of bio-
marker expression patterns that improve intermediate staging and
grading of clear cell renal cell cancer. Clin Cancer Res 2010;16:
88–98.
41. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C,
HoffmanEW,et al. Vaccinationwith anNY-ESO-1peptideofHLAclass
I/II speciﬁcities induces integrated humoral and T cell responses in
ovarian cancer. Proc Natl Acad Sci U S A 2007;104:12837–42.
42. BossCN,GrunebachF, Brauer K, HantschelM,Mirakaj V,Weinschenk
T, et al. Identiﬁcation and characterization of T-cell epitopes deduced
fromRGS5, a novel broadly expressed tumor antigen. Clin Cancer Res
2007;13:3347–55.
43. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb
E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T
lymphocytes in a human melanoma. Science 1995;269:1281–4.
44. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL.
Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:
558–72.
45. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer
therapy. N Engl J Med 2005;353:172–87.
46. KondoE,Maecker B,WeihrauchMR,WickenhauserC, ZengW,Nadler
LM, et al. Cyclin D1-speciﬁc cytotoxic T lymphocytes are present in the
repertoire of cancer patients: implications for cancer immunotherapy.
Clin Cancer Res 2008;14:6574–9.
47. Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA.
Identiﬁcation of a human cyclin D1-derived peptide that induces
human cytotoxic CD4 T cells. PLoS ONE 2009;4:e6730.
48. Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Ram-
mensee HG, et al. Identiﬁcation of a naturally processed cyclin D1 T-
helper epitope by a novel combination of HLA class II targeting and
differential mass spectrometry. Eur J Immunol 2004;34:3644–51.
49. Shi FD, Zhang JY, Liu D, Rearden A, Elliot M, Nachtsheim D, et al.
Preferential humoral immune response in prostate cancer to cellular
proteins p90andp62 in apanel of tumor-associated antigens. Prostate
2005;63:252–8.
50. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, et al. Cyclin D1 as a
universally expressed mantle cell lymphoma-associated tumor anti-
gen for immunotherapy. Leukemia 2009;23:1320–8.
Cyclin D1–Speciﬁc T-cell Responses in ccRCC
www.aacrjournals.org Cancer Immunol Res; 1(5) November 2013 295
on January 28, 2015. © 2013 American Association for Cancer Research. cancerimmunolres.aacrjournals.orgDownloaded from 
Published OnlineFirst September 25, 2013; DOI: 10.1158/2326-6066.CIR-13-0113 
95
96 
 
10. Curriculum vitae : Ali Bransi 
Date of Birth 23/09/1985 
Nationality Canadian 
Education 
09/2009 – 04/2015 University of Zurich, Switzerland 
 Ph.D. student in the lab of Prof. Dr. Maries van den Broek 
 Thesis: Effective immunotherapy of advanced cancer in mice 
09/2007 – 06/2009 Laval University, Canada 
 Master of Science in molecular and cellular biology 
 Functional and structural basis for a phage homolog of human RAD52 
09/2004 – 05/2007 Laval University, Canada  
 Bachelor of Science in microbiology including international program 
09/2002 – 05/2004 Campus Notre-Dame-de-Foy, Canada 
 Diploma of college education in natural sciences 
09/1997 – 06/2002 Louis-Jobin High School, Canada 
 High school degree 
Awards 
2011 – 2014 Fonds de recherche du Québec – Santé 
2010 W.L. Mackenzie King Memorial Open Scholarship 
2008 ACFAS-Desjardins prize of excellence for student-researcher 
2007 – 2009 Natural Sciences and Engineering Research Council of Canada  
2007 Fonds de recherche du Québec – Santé 
Selected publications and communications 
Bransi A., Salgado O. C., Beffinger, M., Milo, K., Yagita H., Becher B., Knuth A. and van den 
Broek M. Effective immunotherapy of advanced cancer in mice. 2015. Submitted manuscript. 
Dannenmann S., Hermanns T., Bransi A., Matter C., von Boehmer L., Stevanovic S., Schraml P., 
Moch H., Knuth A. and van den Broek M. Spontaneous peripheral T cell responses towards the 
tumor-associated antigen Cyclin D1 in patients with clear cell renal cell carcinoma. Cancer 
Immunology Research. 2013. 1: 288-295. 
Ploquin M., Bransi A., Paquet E., Stasiak A., Stasiak A., Egelman E., Moineau S. and Masson J.-Y. 
Functional and structural basis for a bacteriophage homolog of human RAD52. Current Biology. 
2008. 18: 1142-1146. 
Ploquin M., Petukhova G., Morneau D., Dery U., Bransi A., Stasiak A., Camerini-Otero D. and 
Masson J.-Y. Stimulation of fission yeast and mouse Hop2-Mnd1 of the Dmc1 and Rad51 
recombinases. Nucleic Acids Research. 2007. 35: 2719-2733. 
Languages 
French (native speaker), English (near native / fluent) 
Extracurricular activities and hobbies 
Planning of the monthly cancer biology PhD students gathering 
